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There is limited research considering the personal experiences of individuals 
living with or at risk for developing behavioral variant frontotemporal dementia (bvFTD). 
FTD is known to have a significant genetic contribution. With advances in understanding 
the genetic component of FTD, rates of predictive and symptomatic genetic testing will 
increase. Though FTD is the second most prevalent cause of early-onset dementia after 
Alzheimer disease (AD), there is substantially more literature related to AD experiences. 
In dementia research broadly, care partners rather than persons diagnosed tend to be the 
informants. The data presented in this paper are derived from an exploratory project 
called Voices of Individuals: Challenges and Experiences of Behavioral Variant 
Frontotemporal Dementia (VOICE Of bvFTD) that qualitatively explores the specific 
experience of living with bvFTD diagnosis and risk from the perspective of the persons 
diagnosed and at-risk. Semi-structured telephone interviews were conducted to 
qualitatively explore how bvFTD may influence an individual’s sense of identity, 
individuals’ experiences of loss, how individuals cope and adapt to the challenges they 
face, and other factors that might be perceived to influence these processes. Participants 
with a diagnosis of bvFTD (n=6) and with genetic testing results conferring high risk of 
developing bvFTD (n=14) were recruited through two academic medical centers, the 
National Institutes of Health, ClinicalTrials.gov, and through FTD support resources. 
Interviews were transcribed and underwent thematic analysis. This paper considers how 
identity was shaped by the threat of developing FTD among the at-risk subset of VOICE 
Of bvFTD participants (n=14). Participants varied in their conceptualizations of their 
status, how they integrated FTD risk information into their current identity, and how they 
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anticipated changes to their identity in the future. FTD risk raised fundamental issues 
related to what constitutes the essence of a person, challenged people to wrestle with 
Cartesian dualism, and exposed the roles of time, social relationships, and social roles in 
the understanding of the nature of self. Understanding how at-risk individuals reconstruct 
their identities in response to their FTD risk status can inform clinical care, resource 
development, and future research.  
 
Thesis Committee 
Lori Erby, PhD, ScM, CGC (advisor, reader)  
Program Director of JHU/NIH Genetic Counseling Training Program    
 
Jill Owczarzak, PhD (committee member, reader)  
Associate Professor, Health, Behavior & Society, Johns Hopkins Bloomberg School of Public Health  
  
Weiyi Mu, ScM, CGC (committee member)  
Genetic Counselor, McKusick-Nathans Department of Genetic Medicine, Johns Hopkins University 
 
Murray Grossman, MDCM, EdD (committee member)  




















I am so grateful to everyone who has helped to make this project a reality. The 
below acknowledgements cannot begin to capture the true magnitude of support that I 
have felt.  
To my advisor, Lori Erby: You have been the biggest support in every sense of 
the word throughout the entire thesis process. Without your guidance, encouragement, 
and dedication of many hours of brain space, this project would not have been possible. I 
have learned so much from you, and you will always be a mentor and role model for the 
counselor and researcher I hope to become.  
To my committee members, Jill, Weiyi, and Murray: Thank you for your 
willingness to endure many hours of meetings, and for your fantastic ideas, 
encouragement, thoughtful critiques, and expertise. Thank you, Jill, for your qualitative 
expertise and your guidance from study design through thesis reading. Thank you, Weiyi, 
for your clinical expertise and your practical input; I look forward to collaborating with 
you as a neurogenetics colleague. Thank you, Murray, for introducing me to this 
wonderful field, for always encouraging me to pursue my research ideas, and for the 
support of the Penn FTD Center in study recruitment.  
To my classmates, Hannah, Diana, and Alexis: You have been wonderful 
colleagues and companions throughout this two-and-a-half-year journey. Your intelligent 
insights have shaped this project and my genetic counseling training, and for that I am 
forever grateful.  
To my wonderful study participants: It has been an honor to hear your 
experiences. Your willingness to share your time and to discuss incredibly difficult and 
personal experiences will help others in their journeys to make sense of their own genetic 
statuses and FTD diagnoses. You have taught me so much, and I admire your strength, 
your honesty, your hope, and your resilience. 
To my family and friends, especially my parents, Jake, and my roommates: Thank 
you for supporting me emotionally throughout my thesis process and genetic counseling 
training. Your endless hugs and open ears have allowed me to push forward despite many 
hurdles. I appreciate your willingness to listen to me talk about this topic over the past 
two years, and hope you are ready to continue hearing about it as I enter the workforce. I 
feel so lucky to have you all in my life. 
There are several institutions that were instrumental in this project. Thank you to 
the National Human Genome Research Institute at the National Institutes of Health (NIH) 
for financial and technical support. I have deep gratitude for Dr. Mary Kay Floeter and 
Jennifer Farren for their assistance with recruitment at the NIH. Thank you to Jessica 
Bove for recruitment assistance at the University of Pennsylvania. I thank the Johns 
Hopkins Bloomberg School of Public Health and the University of Pennsylvania for their 





Abstract .............................................................................................................................. ii 
Acknowledgements .......................................................................................................... iv 
List of Tables .................................................................................................................... vi 
Introduction ....................................................................................................................... 1 
Frontotemporal Dementia ...................................................................................... 1 
Dementia Worry, Personhood, and Patienthood .................................................... 3 
Identity and the Self ................................................................................................ 4 
Rationale for Current Study .................................................................................... 6 





Results .............................................................................................................................. 18 
Conceptualization of FTD as a Threat to Identity ................................................ 21 
“How Will I Know?”: Enduring Uncertainty & Dread ....................................... 24 
Centrality of FTD Risk Status to Identity .............................................................. 30 
Discussion......................................................................................................................... 38 
Practice Implications ...................................................................................................... 48 
Appendices ....................................................................................................................... 53 
Appendix I: Consent Documents ............................................................................53 
Verbal Consent Script ............................................................................... 53 
Consent Information Sheet ........................................................................ 58 
Consent Comprehension Assessment ........................................................ 62 
Appendix II: Assessments .......................................................................................63 
Demographics Questionnaire ................................................................... 63 
T-CogS ...................................................................................................... 65 
Insight Probe ............................................................................................. 69 
Appendix III: Interview Materials .........................................................................70 
At-Risk Interview Guide ............................................................................ 70 
Diagnosed Interview Guide ...................................................................... 75 
Interview Summary Sheet .......................................................................... 80 
Appendix IV: Recruitment Materials .....................................................................81 
Recruitment Prompts ................................................................................ 81 
Recruitment Letter .................................................................................... 84 
Recruitment Post ....................................................................................... 85 
Recruitment Flyer ..................................................................................... 86 
References ........................................................................................................................ 87 






List of Tables 
 
Table 1. VOICE Of bvFTD recruitment distribution by site and participant category….13 
Table 2. Demographics and summary of characteristics of at-risk study sample……….19 






Frontotemporal dementia (FTD) is a neurodegenerative disease characterized by 
progressive atrophy in the frontal and temporal regions of the brain that causes 
progressive changes in behavior, personality, language and cognition (Deleon & Miller, 
2018). FTD is the second most prevalent cause of early-onset dementia after Alzheimer 
disease (AD) (Piguet et al., 2011). There is a significant genetic contribution to FTD 
(Rohrer et al., 2015; Warren et al., 2013; Onyike & Diehl-Schmid, 2013). Though there 
are multiple FTD phenotypes, this research focuses on the type that is both the most 
common and the most likely to be inherited: behavioral variant frontotemporal dementia 
(bvFTD) (Deleon & Miller, 2018; Seelaar et al., 2008).  
There is a growing understanding of the link between FTD and amyotrophic 
lateral sclerosis (ALS). A pathogenic repeat expansion of C9ORF72 is the most common 
mutation associated with familial FTD and FTD/ALS; it explains much of the co-
occurrence of FTD and ALS in the same individual or within a family (Fong, Karydas, & 
Goldman, 2012). There are several other genes that impart dual risk for FTD and ALS 
including TARDBP and VCP (Synofzik et al., 2014; Guerreiro et al., 2015), and other 
genes that are associated with risk for just one condition, such as GRN which is only 
associated with FTD risk (Nguyen et al., 2018). Though FTD and ALS experiences are 
often intertwined, the Voices of Individuals: Challenges and Experiences of Behavioral 
Variant Frontotemporal Dementia (VOICE of bvFTD) project and this manuscript 
primarily focus on FTD experiences. 
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Individuals with bvFTD experience a progressive loss of interpersonal and 
executive skills. Persons diagnosed may exhibit disinhibition and personality change 
through inappropriate comments, hyperorality, lack of personal hygiene, excessive 
gambling, apathy, repetitive or compulsive behaviors, blunted affect, lack of empathy, 
and mental rigidity (Piguet et al., 2011; Warren et al. 2013; Deleon & Miller, 2018). 
Often, the beginning stages of disease resemble personality disorder-like changes, with 
later progression causing speech/language and cognitive loss. Many of the early 
symptoms involve breaking social norms, which presents challenges for care partners, 
loved ones that provide the primary emotional and practical support for the affected 
individuals (Massimo, Evans, & Benner, 2013a), in addition to the patients themselves. 
At the time of bvFTD onset, individuals are often in a relationship with dependent 
children and have a career upon which the family may be financially dependent (Shnall et 
al., 2013; Merrilees & Ketelle, 2010), causing unique social and financial challenges.  
Greater understanding of the genetics of FTD has allowed for predictive genetic 
testing for unaffected family members of affected persons (Benatar et al., 2016). The 
Huntington disease (HD) protocol is currently the recommended guideline for predictive 
testing for FTD and other neurodegenerative diseases (Sorbi et al., 2012). As Crook et al. 
(2017) note, few studies to date have focused on issues related to predictive genetic 
testing for FTD or ALS, and to the best of our knowledge our study is the first to focus 
specifically on individuals at risk for both ALS and FTD due to genes that cause both 
diseases such as C9ORF72. The majority of the previous studies that focused on 
predictive testing for ALS and FTD were quantitative in nature and were most often 
designed to determine whether predictive testing is safe for this population (Molinuevo et 
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al., 2005; Steinbart et al., 2001; Paulsen et al., 2013), rather than understanding the 
broader psychological and social impact. As predictive genetic testing and diagnostic 
testing are increasingly utilized, many individuals have become aware of their likely 
future disease progression prior to the onset of the most severe or challenging symptoms. 
The group of individuals with knowledge of their genetic status is an emerging 
population that will continue to grow as better understanding of the genetics and 
continued improvement of diagnostic criteria improve the ability to identify individuals 
with bvFTD.  
Dementia Worry, Personhood, and Patienthood 
 
 Dementia is a commonly feared diagnosis for many reasons. Dementia worry is a 
phenomenon that has been documented in healthy individuals with and without family 
history of dementia, as well as in those with early stages of AD (Kessler et al., 2012; 
Clemerson, Walsh, & Isaac, 2014). A key element of dementia worry is the threat to 
personhood and identity: dementia threatens the physical self, the identity as a human 
being, as well as the perception of a shared reality with others (Kessler et al., 2012). In 
the context of dementia, “personhood” describes a person’s sense of self as an 
autonomous and whole entity who has purpose, self-worth, can experience peace and joy, 
can think, feel, make consistent choices, express individuality, and participate in 
meaningful social interactions (Touhy, 2004). Personhood is shaped both by a person’s 
internal sense of self and by social factors such as how a person is viewed and treated by 
others (Boykin & Schoenhofer, 2001). The social context may include family, 
friendships, employment, and even research and clinical care contexts; social factors can 
be particularly threatening to personhood in the context of dementia (Kitwood, 1997).  
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 One type of threat to personhood is “patienthood,” which refers to a person’s 
diagnosis and status as a patient becoming defining features of identity and narrative 
(Sabat et al., 2011). Centrality of patienthood to identity facilitates marginalization and 
negative stereotyping by creating a focus on difference and otherness (Sabat et al., 2011). 
Patienthood may present a threat to personhood by undermining one’s sense of 
wholeness, self-worth, or other elements of personhood previously described. Diseases 
such as dementia that result in loss of independence, loss of skills, and need for frequent 
medical visits may be especially prone to cause a sense of patienthood.   
Identity and the Self 
 
The concepts of identity and self are difficult to define and related research has 
been based on a number of different models (Caddell & Clare, 2010). Various terms such 
as self, selfhood, identity, and personhood attempt to capture the essence of the individual 
(Tolhurst et al., 2014). In developmental and personality psychology, identity is often 
defined in terms of cognitive self-structure, who people believe themselves to be 
(Topolewska-Siedzik & Cieciuch, 2019). The majority of identity development research 
has focused on adolescence, as that is thought to be the most dynamic period in identity 
formation, although identity continues to develop across the lifespan (Topolewska-
Siedzik & Cieciuch, 2019; Crocetti, 2018; Kroger et al., 2010). In a quantitative study of 
3,216 healthy individuals aged 18-65 years, Topolewska-Siedzik and Cieciuch (2019) 
found that identity structure becomes more cohesive and well-functioning with age, and 
that role definition peaks in middle and late adulthood, the time at which bvFTD most 
often strikes and disrupts established roles. With genetic testing becoming more 
commonly pursued among diagnosed individuals, early to middle adulthood is often 
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when relatives of diagnosed persons first learn of their risk status and when they are first 
presented with the opportunity to pursue genetic testing. Thus, bvFTD presents a threat to 
established identity, and bvFTD risk often first appears as a threat in a formative period 
of identity construction. 
Identity is formed by the individual’s perception of the self as a continuous being, 
through past and present attributes, and through interactions with the social world that 
foster social identities (Tolhurst et al., 2014; Sabat et al., 2011). Dementia threatens 
identity by challenging all core pieces of what is thought to make a person a person. 
Little is known about how individuals at risk for developing dementia perceive, react, and 
adjust to these threats.   
Several qualitative studies summarized by Spreadbury and Kipps (2017) have 
shown not only that early-onset dementia poses a threat to identity, but also that the 
impending loss of self may be sufficient to elicit grief responses. Individuals with early 
stages of young-onset dementia and their unaffected relatives express uncertainty 
surrounding loss of personhood; people fear the end of the self rather than physical death 
and are unable to imagine who they “will be” or how they will “think” if they develop 
dementia (Roach et al., 2008). This relates to a specific type of loss known as ambiguous 
loss in which a person is physically present yet psychologically absent (Boss,1999). 
Individuals with or at risk for developing bvFTD may feel a sense of loss regarding their 
identity and previously held ideas of the future. The very nature of FTD raises questions 
that reflect broader philosophical and psychological questions about the relationship 
between the mind, the body, and identity. Kitwood and others who have theorized about 
personhood as described above work within the Cartesian personhood framework that 
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separates the mind from the body, known as Cartesian dualism; in the context of 
dementia, the Cartesian perspective suggests that the person with dementia is mindless 
(Dewing, 2008). Since one aspect of personhood is the perception of the self as a 
continuous being, loss of the mind, and therefore cognition and memory, is a direct threat 
to personhood.  
Exploration of these topics is crucial for the development of supportive 
interventions (Rentz, Krikorian & Keys, 2005). Individuals at risk for bvFTD may have 
experiences with redefining identity that differ in meaningful ways from those at risk for 
other more commonly studied neurological diseases such as Alzheimer disease due to the 
characteristic FTD presentation of changes in personality and social functioning, 
impairments that go beyond cognitive decline. While there has been some research that 
quantitatively assesses psychological outcomes after predictive genetic testing for 
neurodegenerative conditions in order to establish the safety of conducting such testing 
(Molinuevo et al., 2005; Steinbart et al., 2001; Paulsen et al., 2013), these studies have 
failed to consider more nuanced effects of learning risk status, and very few studies have 
considered those at risk for developing FTD. Thus, consideration of how identity 
reconstruction occurs after learning genetic risk for bvFTD is warranted. 
Rationale for Current Study 
 
FTD is incompletely understood from a clinical, genetics, psychological, and 
social standpoint. There has been little learned about the psychological impact of 
awareness of genetic risk for FTD. Improvements in clinical criteria and increased 
availability of genetic testing are resulting in more diagnoses being made at earlier ages, 
and more family members will be recognized as being at-risk. Individuals will 
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increasingly learn of their high risk for developing FTD prior to disease onset or decline 
in awareness with predictive genetic testing, and therefore attention is needed to address 
potential psychological and social implications of living at risk for bvFTD. Importantly, 
this is an emerging population for which clinical trials are becoming available.  As more 
is learned about FTD and the growing promise of possible future drug therapy trials for 
at-risk individuals, rates of predictive genetic testing are likely to increase (Crook et al., 
2017). Since more individuals will be identified as being at risk for FTD and at earlier 
ages, it is important to further our understanding of individuals’ experiences and needs. 
There has been a recent movement in research towards understanding the ‘lived 
experience’ of people with young-onset dementia, although efforts thus far have focused 
specifically on the diagnostic experience (Spreadbury & Kipps, 2017; O’Malley et al., 
2019) and have not considered the experience of at-risk persons who have learned their 
genetic status. There has not yet been an in-depth investigation of how people at risk for 
developing bvFTD experience and adapt to their changing identity and threat to 
personhood, or how they might experience loss. Thus, the VOICE Of bvFTD project 
aimed to gather a deeper understanding of experience to better inform clinical practice, 
resource development, and future studies.  
At its core, genetic risk for FTD raises fundamental questions for participants 
about their sense of self and identity. It brings out theoretical issues related to what 
constitutes the essence of a person, challenges people to wrestle with Cartesian mind-
body dualism, and exposes the roles of time, social relationships, and social roles in our 
understanding of personhood. For individuals at known genetic risk of developing FTD, 
the potential for altered identity is twofold: change in identity due to the nature of the 
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FTD disease process and change in identity as a person living at risk. Thus, at-risk 
individuals must grapple with how identity may change with disease onset in the future, 
as well as how identity has and continues to change as a person living with knowledge of 
their FTD risk. In this paper we explore how FTD and the related disorder ALS present 
threats to identity, discuss the questions this raises for people at risk such as the 
uncertainty of when symptoms will develop and associated emotional valence of dread, 




















 The participants of this study are a subset of the cohort of participants recruited 
for the VOICE Of bvFTD project. For the VOICE Of bvFTD project, individuals with a 
diagnosis of bvFTD or with genetic testing results conferring high risk of developing 
bvFTD were recruited through two academic medical centers, the National Institutes of 
Health, ClinicalTrials.gov, and through FTD support resources. There were two sets of 
inclusion criteria for VOICE Of bvFTD: one for diagnosed individuals and one for at-risk 
individuals. Eligible diagnosed adults were those who had a possible or probable 
diagnosis of bvFTD as per diagnosis by a neurologist, psychiatrist, or group consensus in 
a specialized dementia center if recruited through a clinical or clinical research site, or by 
self-report if through another site. Such individuals must have had symptom onset not 
more recently than two months prior to the interview date. Eligible at-risk adults were 
those who had genetic testing that identified a pathogenic variant in a gene known to 
confer high risk of developing FTD or a known familial mutation associated with FTD, 
confirmed by the individual's dementia or genetics provider or researcher, or by self-
report if recruited through non-clinical or research sites. Such individuals must have had 
the genetic testing result disclosed not more recently than two months prior to the 
interview date. All research participants had to be 18 years of age or older and had to 
speak fluent English. This paper includes data from the at-risk participant cohort from the 
VOICE Of bvFTD project. 
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Procedure 
Individuals from the two academic hospital recruitment sites who met inclusion 
criteria were identified from institutional databases by genetic counselors and researchers 
who assisted with recruitment for the VOICE Of bvFTD project at each site. Recruiters at 
the academic hospitals had clinical or research relationships with the individuals they 
were recruiting. An investigator at the NIH with extensive experience in 
neurodegenerative disease research identified individuals that met inclusion criteria from 
existing NIH dementia research cohorts. Potential participants were contacted through 
their existing clinical or research relationships via mail, e-mail, or telephone based on 
available contact information and preference of the recruiter. Any participant recruited 
through an academic hospital signed a HIPAA authorization form prior to the consent 
process. Individuals at the Penn FTD Center Caregiver Conference were provided with 
study flyers and contacted one of the authors (LD) if interested. Posts were made to 
ClinicalTrials.gov and a private C9ORF72 Facebook group. 
All study participants were provided with a written document that outlined the 
information covered in the verbal consent conversation prior to the consent phone call. 
Participants were encouraged to share the consent document with family members or 
support persons as they decided whether they would like to participate. Participants were 
also provided with a demographics form that they were asked to fill out prior to the 
consent phone call. Every participant participated in a consent phone call with LD. 
During this phone call, LD reviewed the consent information and confirmed eligibility by 
confirming inclusion criteria via collecting demographics information, as well as 
performing a consent comprehension assessment (Appendix I). After verbal consent was 
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given for the study, participants were scheduled to have a telephone-based interview with 
LD. For participants recruited from academic sites, basic medical information was 
collected from recruiters at the academic institutions after receipt of a signed HIPAA 
authorization form. For participants recruited from other sites this information was self-
reported as part of the demographics survey.  
To provide additional descriptive information on participants, just prior to the 
interview, each completed a brief nondiagnostic cognitive assessment via the Telephone 
Cognitive Screen (T-CogS) and insight probe after confirming that they still wanted to 
participate in the study.  Each participant completed an approximately 40-90-minute 
interview that was audio-recorded and later transcribed. Phone interviews were 
conducted by LD between June and August of 2019. The interview was conducted using 
a semi-structured interview guide. If diagnosed participants requested that their care 
partner be with them during the interview then the care partner was allowed to join 
without responding to the interview questions. Three diagnosed participants had care 
partners present during their interviews for question clarification if needed. Several 
diagnosed participants completed the interview alone but had care partners who 
facilitated the research connection and were accessible if necessary during the interview. 
Immediately after the interview, the interviewer (LD) recorded notes on her reactions to 
the interview, major themes that arose, questions that did or did not resonate with the 
participant, and suggestions for future interviews. 
Approximately 129 individuals were contacted about the VOICE Of bvFTD 
project. Thirty-seven individuals were reached during recruitment and expressed interest 
in participating in the study. They were sent study information packets and an invitation 
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to schedule consent phone calls. One individual declined participation at this point. Five 
individuals were identified as ineligible: two individuals were unable to consent due to 
their inability to pass the comprehension assessment and therefore did not meet inclusion 
criteria, and three individuals did not meet other inclusion criteria. Four individuals were 
lost to follow up. Once twenty interviews were completed, recruitment was paused. The 
remaining seven individuals are on a recruitment waitlist. Therefore, not including the 
individuals on the waitlist, the current response rate is approximately 15.5% (20/129). Of 
the twenty total participants, eleven were recruited from the University of Pennsylvania, 
seven from the NIH, one from a conference, and one from a Facebook group. Table 1 
depicts recruitment by site and participant category. Twenty interviews and 
questionnaires were collected; fourteen were from participants with genetic risk for 













Table 1. VOICE Of bvFTD recruitment distribution by site and participant category. 










Johns Hopkins 14 2 0 0 0 
University of 
Pennsylvania 
33 16 5 6 11 
NIH 17 10 7 0 7 
Conference ~30 2 1 0 1 
ClinicalTrials.gov unknown 5 0 0 0 
Facebook group ~35 2 1 0 1 
Total ~129 37 14 6 20 
 
Instrumentation 
Telephone Cognitive Screen (T-CogS): The T-CogS is a brief, valid, telephone-
adapted version of the Mini-Mental State Exam (MMSE) (Kennedy et al., 2014). It takes 
up to ten minutes to complete (Newkirk et al., 2004). The T-CogS was modified slightly 
to reflect the updated telephone technology in question-wording and permitted responses.  
The T-CogS can be found in Appendix II.  T-CogS scores were used to characterize the 
population and to allow for a measure to assess insight described below.  
Insight Probe:  Two questions were asked that prompted the participant to 
consider his or her performance on the T-CogS. While this was not a comprehensive 
assessment of insight, it provided a glimpse into the individual’s awareness of his or her 
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mental capabilities. This probe took about 2 minutes per participant. The insight probe 
can be found in Appendix II. The purpose of this probe was to get a limited but basic 
understanding of to what extent insight was preserved, especially among diagnosed 
participants. This provided context for interpretation of the diagnosed participants 
interviews. If diagnosed individuals were to perform poorly on the T-CogS or insight 
probe, this would provide a nuance to consider when interpreting their interview 
responses. 
Demographic Survey: Basic demographic information was collected from all 
participants. The survey also included several questions about experience with FTD and 
ALS such as whether there are other affected individuals in the family. See Appendix II.  
Medical Information: Limited medical information was collected about 
participants. Information collected included diagnosis type (bvFTD or asymptomatic), 
genetic status (whether they have had genetic testing or not, positive or negative if had 
genetic testing) and which gene harbors the mutation if positive. 
An interview guide was developed to reflect the specific aims of the study. The 
guide consisted mostly of open-ended questions with follow-up prompts to elicit specific 
information from the participants. Two versions of the guide were created such that the 
wording reflected the status of the participant as diagnosed or at-risk; both guides are 
available in Appendix III. The interview guide focused on experiences with FTD, but 
given the overlap between FTD and ALS, some experiences with ALS were explored. 
The major sections of the interview guide centered upon the FTD journey, personhood 




Interviews were audio-recorded. All interview recordings were transcribed by a 
third-party transcription company. Transcripts and observation notes were uploaded into 
MAXQDA, qualitative software that facilitated the coding and analysis process. 
Interview transcripts were coded and analyzed solely by LD using thematic analysis to 
identify common patterns and themes among the interviews. Interviews were analyzed in 
order to describe the ways that participants perceive their identity, discuss experiences of 
loss, and the coping strategies used to overcome the challenges posed by the disease. 
Several a priori codes were created based on topics from the interview guide, such as 
“coping mechanism,” “reasons for testing” and “identity.” The codebook was expanded 
with codes that emerged from the data, such as “genetics identity,” “mortality,” and 
“control.” The preliminary codebook was applied to several transcripts from participants 
who were classified as at-risk and diagnosed. As transcripts were coded, the codebook 
was revised to include emerging concepts and previously coded transcripts were re-coded 
to incorporate any new codes. Eventually, code saturation was reached with no additional 
codes or concepts identified in subsequent transcripts (Hennink et al., 2017) and therefore 
the final codebook was confirmed. Though the codebook was developed and applied by a 
single coder (LD), the coder consulted with JO and LE, who have extensive experience in 
qualitative research, throughout the process, sharing coded segments of transcripts and 
discussing interpretations.  
Qualitative analysis was performed using thematic analysis, which involves 
considering patterns and themes across the data. We investigated in what context the 
codes arose in the data, and how concepts may be interacting. Themes were analyzed 
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within the context of participants’ experiences living with or at risk for FTD. Coded data 
within each theme were reviewed to select representative quotations from participants. 
Data collected from the demographic questionnaire and T-CogS/Insight probe measure 
was used to characterize the population. Data were analyzed across all interviews but 
with consideration of ways in which those who have developed symptoms may have 
differing experiences and viewpoints than those who have not developed symptoms. 
During the coding and analysis process for the VOICE Of bvFTD project it 
became clear that while there were some similarities in experience between at-risk and 
diagnosed participants, there were also many nuanced differences that made it difficult to 
consider at-risk and diagnosed experiences together. Consequently, we decided to solely 
consider the at-risk participant experience in this manuscript; the diagnosed experience 
will be important to explore in a future paper. Thus, this manuscript only considers the at-
risk subset of the VOICE Of bvFTD project participants (n=14) in the analysis. 
Interviews uncovered many themes, not all of which are described herein. This paper will 
focus on how at-risk participants conceptualized their identity and how those 
characterizations had been informed by their risk of developing FTD. Specifically, this 
paper considers the dual threat to identity for at-risk participants: the impact of the 
disease itself and the uncertain status of being at risk. In order to explore these concepts, 
several codes were examined including identity, genetics identity, sick vs. healthy, ALS 
vs. FTD, and status acknowledgement. Interactions between these codes and codes for 
fears, imagined future, and finding optimism/hope/strengths were considered. 
Representative quotations were identified after fully exploring each theme. Demographic 
information was used to consider whether individuals with shared characteristics, such as 
17 
time since genetic testing and age, seemed to share elements of their experiences. 
Broadly, experiences did not seem to differ based on these characteristics, but relevant 



















 This manuscript considers only the data from at-risk participants (n=14) in the 
VOICE Of bvFTD project cohort. At-risk participants had genetic testing between several 
months and seven years prior to study participation, with a mean of 2.07 (SD= 1.87) 
years since testing at time of participation. The study sample was 100% Caucasian 
(n=14), comprised of more females (n=10) than males (n=4), and well-educated with all 
at-risk participants having a college (n=5) or graduate (n=9) degree. Participant ages 
ranged between 31-63 years. All participants scored above 23 on the T-CogS, 
corresponding with the cognitively normal range on the MMSE. All participants had 
good insight into their performance on the T-CogS with most (n=10) estimating their 
exact score and the remaining (n=4) estimating only one point off from their actual score. 













Table 2. Demographics and summary of characteristics of at-risk study sample. 
Characteristic At-Risk Participants (N=14) 
Range of age at recruitment (years) 31 - 63 
Gender (N, %) Female (10, 71.4%) 
Male (4, 28.6%) 
Race (N, %) White/Caucasian  
(14, 100%) 
Gene Involved (Gene – N) C9ORF72 - 11 
GRN - 2 
TARDBP - 1 
Education (Highest Achieved – N)  College graduate – 5 
Graduate degree – 9  
Range of age at time of testing (years) 30 - 56 
Approximate years since testing   
Average (Range) 
2.07 (less than 1 – 7) 
T-CogS Score1 (Score – N)  26                              N=7 participants 
25                              N= 6 participants 
24                              N=1 participant 
Self-Perceived Symptoms2  
(Confidence – N)   
0                                N=12 participants 
0-1                             N=1 participant  
1                                N=1 participant 
Doctor-Perceived Symptoms2  
(Confidence – N)   
0                                N=14 participants 
1. Telephone Cognitive Screen (T-CogS): Higher scores convey better performance. Range 0-26. 
Scores of 24-26 indicate normal cognition, and 17-23 indicate mild cognitive impairment. 
2. Symptom perception number line: Participants were asked to endorse how confident they are and 
how confident they think their doctors are regarding their symptom status. 0 indicates confidence that 
the participant does not have symptoms, 2 indicates complete uncertainty about whether they have 
symptoms, and 4 indicates confidence that they do have symptoms. 
 
To protect the identities of the individuals who participated in this study, participants 
were assigned pseudonyms. These pseudonyms and characteristics of the individual 
participants can be found in Table 3.  
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Table 3. Individual at-risk participant characteristics. 











Ella At-risk 59 F Married Yes Retired 3 C9ORF72 
Anna At-risk 63 F Single No Retired 7 C9ORF72 
Mary At-risk 54 F Married Yes Full-Time 3 C9ORF72 
Leigh At-risk 46 F Married Yes Full-Time 3 C9ORF72 
Drew At-risk 47 M Married Yes Full-Time 4 GRN 
Mia At-risk 44 F Married Yes Full-Time 0 C9ORF72 
Britt At-risk 31 F Married No Full-Time 1 C9ORF72 
Nancy At-risk 32 F Single No Full-Time 0 GRN 
Frank At-risk 36 M Married Yes Full-Time 0 C9ORF72 
Eva At-risk 49 F Married Yes Part-Time 1 C9ORF72 
Steph At-risk 39 F Married Yes Full-Time 1 TARDBP 
Ally At-risk 46 F Married Yes Full-Time 2 C9ORF72 
Luke At-risk 44 M Married Yes Full-Time 3 C9ORF72 
Jeff At-risk 31 M Married No Full-Time 1 C9ORF72 
Legend: F=female, M=male, Yrs=years, GT=genetic testing 
 
Like any individual who has had predictive genetic testing for FTD, all 
participants had at least one family member (parent or sibling) with FTD, ALS, or both 
diseases. Thus, almost all participants had cared or were actively caring for someone with 
these conditions and therefore were affected by FTD in ways that had little objectively to 
do with their risk status. Participants’ level of involvement in the care of their affected 
family members varied greatly. For example, some individuals were the primary care 
partners or legal guardians for parents or siblings and therefore had daily contact with 
their family members with FTD, whereas others lived far from diagnosed relatives and 
saw them infrequently with little to no involvement in their care. One participant, Eva 
(female, age 49), only had family history of ALS, not FTD, and several others had more 
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contact with family members who had ALS than those with FTD or FTD/ALS. All 
participants who had relatives diagnosed with FTD described a period of confusion when 
the affected loved one became symptomatic with FTD. This often began as observed 
differences in behavior and personality, as is typical of the disease course. Learning their 
genetic status changed the way they were affected by FTD, but how they integrated this 
information into their identity was undoubtedly shaped by their experience with the 
diseases in their loved ones. 
Participants’ motivations for having predictive genetic testing varied. Many 
participants had testing so that they could provide information to their children, and some 
had testing so that they could pursue alternative reproductive technologies such as in 
vitro fertilization (IVF) with preimplantation genetic diagnosis (PGD) to avoid passing 
down the genetic risk factor. Several participants chose to have testing so that they could 
participate in research studies. Other people just felt that they had to know their status to 
move forward with their lives and to be able to plan appropriately once they learned 
about the genetic risk in the family. 
 
Conceptualization of FTD as a Threat to Identity 
 
At-risk participants universally perceived the FTD disease process as a threat to 
identity. Frank (male, age 36) called C9ORF72-related FTD/ALS his “worst nightmare of 
a disease” that “forces you to become an infant in an adult body.” Mia (female, age 44) 
said that FTD “takes the essence of who you are away-- your personality.” Through 
witnessing family members’ experiences with FTD, participants described the disease as 
“soul destroying” (Ella, female, age 59), and as having the ability to “completely strip a 
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person piece by piece by piece” (Britt, female, age 31). The common theme among these 
sentiments is the notion of FTD as a disease that reduces or strips away the core of 
identity. This sense of reduction and the image of becoming an “infant” demonstrates 
how the person with FTD is deprived of the personhood they acquired through a lifetime. 
Participants described how FTD causes people to retrograde to an earlier or a bare state 
as a reverse aging of sorts. Most participants feared losing their independence, again 
harkening back to the nature of FTD as retrograding. While they used varying language, 
all at-risk participants conceptualized FTD as a fundamentally reducing disease.  
Participants grappled with Cartesian dualism, the philosophical approach that the 
mind is separate from the physical body. Many participants at risk for both FTD and ALS 
noted that they have engaged with the dilemma explicitly, as Frank (male, age 36) asked, 
“The theoretical question of would you rather be able bodied but lose your mind or keep 
your mind intact but lose your ability to use your body.” Participants weighed which 
scenario seemed better or at least less bad. Several participants described how developing 
FTD would destroy who they are by destroying the mind:   
Your brain is who you are.  Once your brain is destructing at that point, you are 
there in body and soul; you're not there in your mind…as my body is shutting 
down, there'll be a progression into somebody I am not now.  I will not be the 
same person I am now…So losing that part for me is like losing me. (Mia, female, 
age 44) 
 
Mia and other participants recognized that who they will be is not who they are now due 
to the disease. Mia’s quote refers to an anticipated form of ambiguous loss of the self: the 
self is physically but not mentally present. This sentiment was also captured by Ella 
(female, age 59) when she said “I want to die the same person that I am,” after she 
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discussed how FTD would change who she was versus ALS in which the mind remains 
intact. Because of this feared loss of self, some participants acted to assert or preserve 
their identity. For example, Mia (female, age 44) decided to create videos for her children 
to document her life story before she was “gone.” Many individuals experienced a threat 
to the permanency of their identity. 
Another consequence of this loss of self is the loss of the self as a social being. 
Jeff (male, age 31) said: 
You lose your personality, your sense of self, your sense of self to others.  You are 
not who you were, you do not act in ways that benefit the way others think of you.  
I think that is scary, just we all are social people and we want to be respected and 
admired and thought of well, and FTD robs you of that. 
Jeff’s description of the impact of FTD echoed the notion of losing pre-disease identity 
and introduced a social component to the loss. Social roles and relationships are a major 
way that people define themselves; by altering behavior and personality FTD degrades 
social status and capabilities.  
In addition to the ways that FTD threatens social relationships, participants 
expressed fears regarding how FTD threatens their future ability to fulfill their social 
roles as parents and spouses. Frank (male, age 36) discussed his worry about how 
C9ORF72-related disease would strip him of abilities and roles that were a source of 
pride:  
It has endangered some of the things that I take pride in as a person… it would 
force me to rely on other people for everything.  It would force me to ask for help. 
It would eliminate my ability to care for my family and protect my family and 
maintain the house we live in and the cars we drive and make sure everyone’s 
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safe, like all those things that I take pride in as a husband and a father…and I’d 
be powerless to stop it. That’s been the worst thing to think about.  
 
Frank’s identity as a father and husband was threatened by FTD and ALS. Similarly, Jeff 
(male, age 31) said he did not want his future children to think of him as an incapable 
father if he changes due to FTD/ALS. Other participants worried about becoming a 
burden or embarrassment for their family members. For example, Luke (male, age 44) 
talked about his fear of a “slow awkward un-dignifying death that bankrupts my family 
and drags them through a bunch of crap.” Through use of the term “un-dignifying” this 
quote also demonstrated the social component to identity perception, as how others 
perceived his demise mattered to Luke.  
 
“How Will I Know?”: Enduring Uncertainty & Dread 
 
While genetic testing can resolve uncertainty related to whether or not an 
individual has a genetic risk factor for developing FTD, a result conferring high risk 
simultaneously engenders further uncertainty related to disease development. There is 
currently no way to predict if or when symptoms will develop, which symptoms will 
develop, or how severe or long a disease course will be for any one individual. Given that 
participants perceived FTD as threatening to identity, it is not surprising that all 
participants at risk for developing FTD described ways in which this uncertainty and 
dread of developing disease had become part of their lives.  
When contemplating how they may change due to FTD, participants used strong 
language that indicated a sense of dread and anticipated negative downturn. Multiple 
participants used language such as feeling “doomed.” Nancy (female, age 32) said, 
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“What’s wrong with me? I’m cursed. I have this gene,” and questioned whether she 
would ever consider herself “normal” again. Frank (male, age 36) summed up the impact 
of this dread: “the fear of what was to come completely derailed my life.” Frank 
described how this fear caused crippling anxiety about developing the disease before 
treatment becomes available, and this resulted in his inability to form and maintain 
relationships or engage in daily activities without worrying about his risk. The risk status 
established an uncertain and ominous future that had present impact on participants’ lives 
and self-perceptions. 
Eva (female, age 49) described the uncertainty of her risk and her 
conceptualization of FTD as a monster: “There's something with glowing red eyes under 
my bed and I know it's a monster. And it's not going to help me to just put a bedspread 
over it. There’s still going to be a monster under my bed.” Eva expressed her desire to 
know as much as she could learn about the “monster” that represented FTD; she needed 
certainty as she was faced with profound uncertainty and a disease so dreadful that it was 
deemed monstrous. Many other participants similarly characterized the uncertainty their 
mutation status rendered as unsettling. Due to this uncertainty, participants were 
reminded of their mortality. Like many other participants, Drew (male, age 47) described 
a shift in his sense of self in which mortality became more salient, feeling his “time 
horizon being foreshortened.” Jeff (male, age 31) described how he viewed both his 
C9ORF72 status and FTD/ALS: “Being gene positive it’s basically a death sentence, and 
the execution style is the worst possible thing known to man…they should put serial 
killers through that not nice people like us.” Knowledge of genetic risk for FTD forced 
people to confront not just their mortality, but also their sense of self as the “execution 
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style” is especially cruel in threatening the core of identity itself. Some participants 
experienced anticipatory grief regarding the potential loss of their expected future. Steph 
(female, age 39) said “you kind of mourn what hasn't happened yet…it took me, oh, a 
good six months to like get used to…the fact that like I'm not going to live to be as old as 
I expected to live.” Thus, the uncertainty related to disease development also resulted in 
grief responses in addition to confronting mortality and the potential loss of the self. 
Most participants knew firsthand what the course of FTD could entail via 
experiences with other family members. Because of this lived experience, participants 
had some idea of the nature of their likely fate, and this increased the sense of dread and 
doom. Luke (male, age 44) said, “It's awful watching your parent or any family member 
go through that and it's just a little icing on the cake to be like, ‘Oh, is that my fate too?’"  
Similarly, Drew (male, age 47) described how his experience caring for his father and 
meeting other families at caregiver conferences eerily foreshadowed what may happen to 
him if he develops FTD:  
 
[At the Caregiver Conference is] when my mutational status hits home and 
makes-- when I am most fearful…because it's presented in front of me. And 
because what I saw my father go through is typical and textbook…and it 
absolutely matches everybody else’s…experience on what's going on with their 
loved ones...I just feel at that point that I’m doomed. That's what’s going to 
happen to me and it's just a matter of time and I just have to live through it. 
For Drew, witnessing the cycle of FTD confirmed the reality of the disease course and his 
trajectory towards the same fate. At-risk individuals have extensive experience with what 
FTD and/or ALS can do to a person; this understanding tends to exacerbate dread and 
makes the threat real, salient, and seemingly inescapable. 
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Many at-risk participants recognized that it is unlikely that they will be the first to 
know that they are symptomatic if they develop FTD, as a characteristic component to 
FTD is lack of awareness or insight into one’s own behavior. This fear of being 
symptomatic without knowing it contributed to participants’ dread of wondering if or 
when they will develop symptoms. Ella (female, age 59) was consumed and stifled by 
self-doubt related to her risk of developing symptoms. She constantly worried that she 
would develop symptoms without awareness and inadvertently hurt herself or others; she 
stated that hurting someone else is what she feared the most: “I have no confidence in 
any decision I make... I'm afraid of doing anything… I don't want to be responsible for a 
huge mistake.” She believed that the inability to trust her own judgement and brain with 
resulting self-doubt was the worst part of her risk.  
As FTD causes people to lose self-awareness, participants devised other ways that 
they would detect the onset of their disease. Some participants confided in friends, 
family, or coworkers about their risk and asked them to inform them if their behavior 
changed. Many also engaged in self-surveillance for symptoms, although this often 
heightened anxiety. When participants forgot something or acted out of character it 
reminded them of their risk and raised worries that they could be symptomatic. For 
example, Nancy (female, age 32) said:  
“I just have to constant[ly] remind myself not to look-- if I forget a word that this 
isn't a sign of symptoms, to not be paranoid of that…I remember after I found out 
I was positive I did lose my keys... I started bawling my eyes out…and that was 
the first time I had a fear. I was like ‘Oh my goodness, the gene.’”  
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All who noted similar worries rationalized that everybody forgets things from time to 
time. However, this surveillance for symptoms heightened many participants’ worries 
about their risk, making the genetic status more salient.  
Although some participants described surveillance for symptoms as related to 
their anxiety about becoming symptomatic, others found comfort in surveillance such that 
performance on cognitive testing and other evaluations from physicians was interpreted 
as proof that they were doing okay. For example, one participant described how 
constantly being checked at neurology appointments and research visits kept her from 
worrying. She said, “I'm like ‘Nope. Don't have it. When I have it, they will tell me,’ so I 
don't feel like I have that constant concern that I have something wrong with me” (Steph, 
female, age 39).  This reliance on surveillance for reassurance was most often utilized by 
those who felt they were “just genetic carriers” or who rejected FTD risk as part of 
identity; these attitudes are described in more detail in the following section. Thus, for 
some people FTD was brought to the forefront of their identity through surveillance, but 
for others surveillance served as a tool to delay the centralization of FTD through 
denouncing its current impact.  
Multiple participants contrasted FTD and ALS onset, emphasizing the nuances of 
FTD that make it harder to detect in the self: lack of self-awareness and its cognitive 
rather than physical nature. These nuances add a complicated layer of uncertainty and 
therefore fear. In addition to having a father with dementia that was assumed to be FTD 
after a C9ORF72 pathogenic expansion was identified in the family, Luke (male, age 44) 
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had many relatives with ALS. Luke noted the difference between anticipating cognitive 
FTD and physical ALS symptoms:  
What was even worse was the concept of the FTD piece because…there are so 
many natural things that could occur to make you question it anyway as opposed 
to for something physical like ALS, it's like, ‘I'm pretty sure I'm okay. I got up and 
didn't drop anything today or trip and fall,’ or whatever right, it's so much less 
clear about this, so that's a little more intimidating than the other.  
Luke recognized that the onset of FTD would not only be much harder for him to detect, 
but that there could also be more opportunities for false alarms. However, wondering 
how and when ALS onset may occur posed its own set of problems for some participants. 
For Frank (male, age 36), the physical nature of ALS led to intense surveillance for 
symptoms. After experiencing some tremors that worsened with anxiety, Frank 
convinced himself he was developing ALS until he eventually had a normal 
electromyogram (EMG). He described his intense ALS self-surveillance prior to having 
the EMG:  
Everything I did in daily life became an ALS test. It sucked all the joy out of my 
workouts…[j]ust fearing that something would feel weaker. Every time I walked 
up the steps it was ALS. Every time I pull[ed] a door handle open, ‘Does it feel 
any different?’ Every single thing I did became a test. I was constantly saying 
tongue twisters to see if I could still enunciate my words clearly.  
While Frank said that he still engaged in surveillance after the normal EMG, he was 
better able to recognize when physical symptoms were due to anxiety. Frank’s experience 
illustrated an all-consuming response to the uncertainty of disease onset, and the benefit 
of evaluation by a physician to at least temporarily quell anxiety.  
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Centrality of FTD Risk Status to Identity 
 
 While an FTD risk designation raised fundamental questions about what 
constitutes self and how a sense of identity is cultivated over a life course, participants 
simultaneously engaged with the threat of FTD diagnosis in their process of identity 
creation. Participants varied in how they dealt with the risk and therefore there were 
varying consequences for how and to what extent their risk was incorporated into their 
identity. The general stances participants took are best described as part of a continuum 
from FTD risk as central to identity to FTD risk as not central to identity.  
 
FTD Risk as Central to Identity: FTD risk became central to identity for many 
participants, although there was variability in terms of the positive versus negative 
valence of these discussions.  While FTD risk was very explicitly a part of identify for 
some, for others, this was discussed in a more subtle way. One participant described how 
his genetic status became a positive part of how he views himself: 
I think that I am the first of a massive population of people who will 
soon…understand their genetic status for a variety of things, and I see myself as 
the pioneer, as Neil Armstrong navigating this world knowing, and so I feel like 
I’ve got a responsibility to tell others, to help others navigate this, to possibly 
facilitate others through this journey. (Jeff, male, age 31) 
 
By labeling himself as a “pioneer,” Jeff assigned himself an identity centered around his 
genetic status. Though no other participants used the label of pioneer, a few highlighted 
their unique status as part of a small group of individuals who are aware of their risk for 
developing symptoms of FTD prior to any possible neurological decline. These 
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participants identified as part of a distinct group of individuals, and one described this 
new identity as being a “rare bird” (Eva, female, age 49). While this rarity was seen to 
confer special status and purpose in some ways, it also conferred isolation to some. Ella 
(female, age 59) said, “It makes me feel so separately from everyone else, and I don't like 
being in a bubble by myself.” For Ella, FTD risk defined her as different and this was 
isolating. In his quote above, Jeff also conveyed a responsibility or obligation to act to 
benefit the FTD community so to speak, such as through advocacy, research, or 
connecting with others. Several other participants expressed similar feelings that spurred 
their research and advocacy involvement. Britt (female, age 31) described how she 
actively decided to make her genetic status part of her life through awareness of and 
involvement in research efforts. Drew (male, age 47) reiterated the value of participating 
in research as an asymptomatic person and referred to himself as “a really good 
pincushion.” Thus, these at-risk participants built a shared identity as a new and perhaps 
pioneering group of individuals with awareness of their risk status without neurological 
impairment. They felt they could contribute uniquely to research, advocacy, and other 
efforts aimed at finding treatment.  
A few at-risk participants assessed their risk in a way that allowed them to 
conclude that they were better people because of the experience of knowing. For 
example, Jeff (male, age 31) stated “I think that I am the same person, probably a better 
person than I was.” He tried to look at life in a more investigative, mindful way and said: 
Now I've got this new perspective on life, and I've gained this nugget of 
wisdom…You kind of take a snapshot. Am I doing it all right...I think that unless 
you have something in your life or someone or some teaching or some training 
that can snap you out of it you will never realize that life could be better.  
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This approach demonstrated the ability of an at-risk identity to fundamentally and 
positively change the way a person viewed him or herself. Jeff (male, age 31) said that 
because of his awareness of his status he was able to “love deeper and harder,” to 
“cherish relationships more,” to feel wiser, and to take on the idea that he was “truly 
blessed.”  
 Some participants referred to themselves as patients despite being asymptomatic. 
This suggests that the genetic status alone was important enough to impart patienthood. 
Nancy (female, age 32) described an experience in a support group that heightened her 
awareness of her risk and ultimately led to her self-characterization as a patient. When a 
man asked if it was wrong that he could not wait until his wife’s battle with FTD ended 
many people said no, and the participant recalled feeling similarly when her own mother 
was sick. However, the participant also described being upset thinking about others 
wishing she would die:  
 
As somebody with the gene, you sit there and think…‘Great. Is my spouse going to 
say that about me? Are my children going to say that about me?’…You look at it 
as the caregiver and the family member of the person who has the disease, but 
now you also look at it as the person with the disease, because that can be you 
now…So when I hear people make that comment, it hurts me in a way that-- they 
don’t know what it’s like to live with the gene. But you can’t be mad, because you 
thought the same thing at one time.  
 
The interviewer followed Nancy’s comment by stating “but your perspective has 
changed,” to which Nancy responded in agreement with “because you’re now technically 
a patient.” As Nancy navigated her roles as both a caregiver and a patient, FTD risk 
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became central to her identity. The risk induced a sense of patienthood, despite her 
asymptomatic status and the lack of clear role definition as she was “technically” but not 
obviously a patient, operating in an uncertain in-between phase. Interestingly, most at-
risk individuals who called themselves patients or expressed similar sentiments still 
distinguished their current state from their anticipated future state: they noted that the risk 
status is not the same as having the actual disease. Participants’ incorporation of 
patienthood into their identities may suggest that these individuals were convinced they 
would develop disease. 
For some participants, the emotional valence of the risk status changed over time. 
Britt (female, age 31) transitioned from being embarrassed about others knowing her 
status to serving as an FTD/ALS advocate. Early on, her friends made a GoFundMe post 
to try to raise funds for the participant and her husband and she was “mortified” after it 
was posted, to the extent that she avoided signing onto social media or going home to her 
small town for fear of a “pity party” (Britt, female, age 31). After that post, she had to 
explain her status to many people. She later chose to get a visible tattoo that symbolized 
her risk; she saw dual purpose to her tattoo, as it served as a means of raising awareness 
and as part of her self-defined coping mechanism. Britt noted that she and her husband 
want to start a foundation using resources from the GoFundMe page to help other couples 
afford IVF with PGD, as they found it to be an expensive and challenging process to 
navigate. This signifies a change in Britt’s relationship to society from someone to be 
pitied to someone who is an advocate. This transformation from humiliation to advocacy 
occurred within about a year after her results were disclosed.  
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FTD Risk as Less Central to Identity: Incorporation of FTD risk into sense of self was not 
universal among at-risk participants. Unlike those for whom FTD risk was central to 
statements about who they were, some participants identified as “just a genetic carrier” 
(Mary, female, age 54) and were readily able to identify other aspects of self that were 
quite separate from their risk status. Many of these individuals had the perspective of “it 
is what it is.” These participants drew on the rationalization that all that had changed due 
to genetic testing was their awareness of their status. For example, one participant said, 
“I was positive from the moment I was conceived. So I'm not any different than I was for 
all those years before I found out” (Anna, female, age 63). Another participant, Luke 
(male, age 44), described how his attitude towards his status evolved over time to reach a 
similar sentiment as Anna: 
I mean it was a certain level of anxiety but not like all the time…Because when 
you think about it as it applies to you, it's sort of like this hasn't happened yet but 
in fact it has.  And then from there it starts to set in, not right away but over time 
that same mentality of well this was-- I've always had this, this isn't new and what 
you sort of have it in that frame of mind, all you really have is insight into what 
your predisposition[ed] for. 
This approach minimized the impact of risk disclosure by prioritizing the notion that the 
risk status itself was unchanged. Part of how Luke arrived at this stance was through 
making downward social comparisons. He described how comparing himself to 
diagnosed individuals participating in research allowed him to conclude that “It's not 
nearly the big deal that you thought it might have been when you first started out.” By 
identifying others who were worse off per se, he felt more positively about his own 
situation and the risk status became less worrisome to him over time. It is possible that 
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many people at risk, like Luke, adjust their stance towards this “just a genetic carrier” 
sentiment over time as they continue to live without symptoms. This in fact was an 
explicit goal for one participant, who felt she needed to find ways to make FTD less 
central to her life. Nancy (female, age 32) described how her FTD risk became a major 
part of her cognition: “It is always going to be on the back of my mind, at least for a 
while until I learn how to deal with it and not let it take over…I can’t let it take over my 
life, but right now it’s only a couple of months old.”  She noted that she tried to diminish 
the centrality of FTD risk to her sense of identity, and compared this process to getting a 
new car:  
You get a new car and that new car is…fresh on your mind. You’re going to be 
talking about it maybe for the first couple months. It’s the same thing. Once 
anything in your life changes, you’re going to talk about it. And then as time 
passed, that car is not important anymore. It’s just a car. 
Thus, after several months with FTD risk central to her identity, Nancy decided that she 
needed to actively prevent the risk from defining her and her thoughts. This entailed 
recognition of FTD as central to identity, as well as a desire and concentrated effort to 
redefine her self-identity in relation to FTD.  
Participants who identified as “just genetic carriers” were people who knew their 
status for at least one year, and like Luke some were able to describe previous attitudes 
towards the status that were more anxious in nature. However, this shift towards a “just a 
genetic carrier” attitude is not universal as some of the individuals who expressed more 
negative and fearful sentiments indicative of a central role of FTD risk in identity 
described above knew their status for three or more years. 
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Thus, for some at-risk participants the genetic status was acknowledged but had 
not become a core element of identity by the time they were interviewed. However, some 
participants who took this “just a genetic carrier stance” and claimed minimal impact on 
their lives still simultaneously described new roles that were shaped by their risk, mostly 
as research participants and advocates. This stance may reflect participants’ attempts to 
cope with risk via cognitively focusing on ways in which they are no different than they 
were prior to testing.   
Other participants completely rejected FTD risk as part of their identity. One 
participant considered herself “a fighter against what [she] consider[s] to be like medical 
injustices,” such as cancer, but felt that she had “other fish to fry” besides FTD, referring 
to ailments of other family members. With regards to FTD she said, “It's important that I 
fight it but I don't consider myself a sick person.” Since she was not symptomatic and did 
not feel that her risk status was affecting her, she chose to focus on others who were sick 
in her life, such as her husband.  The way she viewed her status was, “If somebody had 
told me I had high cholesterol I’d have the same response: ‘Well, that's a pain in the ass. 
Let's take care of it.’ I refer to it as a boil on my butt, if you don't mind my saying. It's 
really just-- it's a nonissue” (Eva, female, age 49). Even though FTD was threatening to 
affect her, she still saw this threat as lesser than the current diagnoses of family members. 
FTD was clearly not integrated into her identity as it took a backseat to other problems of 
loved ones in her life. Other participants who rejected FTD as part of identity similarly 
engaged in this purposeful process of not letting FTD become central to identity. For 
example, Drew (male, age 47) actively chose to not alter his lifestyle or behavior after 
learning his risk. He said by living his life as he would have normally lived it, “[it was] 
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like saying ‘fuck you’ to the mutation and to the disease.” However, such complete 
rejection of FTD risk as part of identity represented the approach of a minority of the at-
risk participants. Thus, the centrality of FTD risk in the identities of participants varied, 


























The purpose of the VOICE Of bvFTD project was to broadly explore how people 
think about their FTD diagnosis or risk, the emotional and behavioral effects of the 
diagnosis or risk, and the related challenges and experiences. In this manuscript, we 
explored how at-risk participants perceived the disease process of FTD as threatening to 
identity and how they incorporated their risk into their current identity. Additionally, we 
considered the questions raised by their risk and associated emotional reactions.  
The limited research considering predictive testing in FTD or ALS has been 
focused on proving that the practice is safe and therefore feasible. Several studies have 
noted that there are no significant psychological implications to learning genetic risk for 
inherited neurodegenerative diseases by examining psychiatric admissions, suicide 
attempts, or lasting severe anxiety or depression (Molinuevo et al., 2005; Steinbart et al., 
2001; Paulsen et al., 2013). However, this does not preclude the existence of difficult 
experiences not able to be captured by the outcome measures used and at the time points 
assessed. Additionally, this focus is too narrow to fully understand the experience of 
predictive testing and its impact. Of note, there is substantially less research related to the 
impact of FTD predictive testing compared to Alzheimer disease (AD) and other 
neurodegenerative diseases such as Huntington disease (HD), for which predictive testing 
has been available for almost two decades (Paulsen et al., 2013; HDSA, 2016). FTD 
results in altered personality and behavior without outwardly appearing motor signs like 
those seen in HD or initial memory impairment that is indicative of AD or other 
dementias. Thus, FTD presents unique challenges and reactions to predictive testing may 
differ. Furthermore, the measurement endpoints for previous studies of FTD and ALS 
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predictive genetic testing were assessed no later than three years post-disclosure which 
limits understanding of longer-term effects (Crook et al., 2017). Though our results fit 
with those of previous studies that suggest predictive testing can generally be performed 
without causing extreme or dangerous psychiatric reactions, our results also suggest that 
how people handle risk information is quite complex, variable from person to person, and 
far from static. Studies of quality of life and other measures designed to assess impact 
after testing need to consider methods to capture these nuances, such as by employing 
mixed-methods designs to consider broader effects and longitudinal designs to capture 
how people incorporate risk over time. Although it is important to establish lack of 
clinically significant psychological impact to justify the safety of predictive testing, to not 
elaborate on the challenges that do occur is a disservice to patients. It would be beneficial 
for providers to understand and discuss with patients the potential consequences of 
testing in pre-test, disclosure, and longitudinal post-test appointments, and therefore 
research needs to consider predictive testing experiences qualitatively in addition to 
reported quantitative measures.  
Furthermore, future research should expand the quantitative outcome measures 
utilized beyond just assessments of severe psychological concerns. As identity 
reconstruction may be conceptualized as part of psychological adaptation, our data 
suggest that future research using a measure of psychological adaptation is warranted, 
such as the Psychological Adaptation Scale (PAS). The PAS is a quantitative assessment 
of adaptation to a chronic condition or disease risk (Biesecker et al., 2013). There are also 
quantitative measures of illness identity such as the Illness Identity Questionnaire (Van 
Bulck et al., 2019). Future research may consider the relationship between these variables 
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to assess how various identity restructuring processes might correlate with overall 
psychological adaptation and functioning to further understanding between these 
processes and outcomes for at-risk individuals. Since our data demonstrate that people 
may evolve in their attitudes towards their risk over time, research should also consider 
the longer-term evolution of identity reconstruction in response to risk to create 
interventions for those who struggle most with their risk status.   
Studies that have assessed individuals’ reasons for or against pursuing predictive 
genetic testing in FTD and ALS have found that some people pursue genetic testing to 
reduce ambiguity or uncertainty (Fanos et al., 2011; Steinbart et al., 2001; Riedijk et al., 
2009), which was also the case for several of our participants. However, while predictive 
testing resolves some uncertainty related to the genetic status itself, it simultaneously 
engenders uncertainty about the future when it reveals a positive result conferring high 
risk of disease development. One major concern for participants in this study was the 
potential for development of FTD without self-awareness of disease. This and other fears 
about the future shrouded some, but not all, participants in unfathomable uncertainty and 
dread. In her work on uncertainty in illness, Mishel (1988) noted that it is not uncertainty 
itself that is inherently dreadful, but rather the implications of the uncertainty as shaped 
by the person’s appraisal of the uncertainty as a danger or an opportunity. Due to the 
perceptions of the FTD disease process as stripping or reducing and the current lack of 
available treatment, it is unsurprising that many people appraised the uncertainty as a 
danger and therefore as dreadful. However, some viewed their risk as an opportunity to 
better themselves or help others. The uncertainty of genetic risk makes psychological 
adaptation challenging (Biesecker and Erby, 2008). Future research should explore what 
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causes some individuals to appraise the uncertainty of genetic risk as opportunity rather 
than danger, determine whether this approach is consistent with more positive 
psychological adaptation, and suggest counseling or other interventions that encourage 
this mindset if it is found to be beneficial.    
At-risk participants were forced to consider what they view as the essence of a 
person, as this is threatened by their conceptualizations of the FTD disease process. Risk 
for FTD raised interesting theoretical questions grounded in Cartesian dualism that led 
participants to grapple with the relationship between mind, body, and identity. The 
ultimate questions underlying participants’ attempts to make sense of their risk were the 
questions “who will I be?”, and “who won’t I be?” if I develop FTD. FTD risk also 
caused participants to confront related existential problems as it increased the salience of 
mortality. Although not described in detail in this manuscript, the majority of the 
participants grappled with the duality of risk for two neurodegenerative diseases, FTD 
and ALS. Future research should further explore how individuals think about and cope 
with the dual risk. 
Most participants described ways they believed or feared their sense of self and 
identity would change in the future. Some participants described loss of psychological 
self despite physical presence as something they anticipated based on experience with 
family members. The physical presence but psychological absence of loved ones with 
dementia has been well-characterized as ambiguous loss (Boss, 2011). Ambiguous loss 
has traditionally been characterized as a relational phenomenon, such that the loss of a 
loved one is unclear due to physical presence with psychological absence as in dementia, 
or psychological presence with physical absence as in missing persons in war or natural 
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disasters (Boss, 1999). However, a novel type of ambiguous loss was identified by 
participants in this study: anticipated ambiguous loss of the self. Participants imagined 
the ways in which FTD would strip them of their core being and feared what identity 
would remain. They feared and grieved the impact this would have on themselves as well 
as on their families, friends, and others. This phenomenon of ambiguous loss of the self 
should be investigated further in other neurologic disorders for which predictive genetic 
testing is available. This should also be further investigated in people with early stages of 
dementia.  
The centrality of FTD risk to identity varied greatly among participants, as did the 
emotional valence of the impact of the risk status on identity. Perhaps in our study altered 
identity is most readily recognized through participants’ redefinition of existing roles and 
creation of new roles. Participants considered what their risk meant for their identities as 
parents, spouses, working individuals, and how it created new identities as research 
subjects, advocates, and patients. The process of refining identity due to FTD risk may be 
part of the psychological adaptation process. The cognitive theory of adaptation provides 
a framework to describe how people adapt through search for meaning, attempt to regain 
mastery or control, and bolster self-esteem in response to threat (Taylor, 1983). Certainly, 
receiving information about a genetic risk status for FTD or FTD and ALS can be 
threatening. As part of the process of adaptation, our participants had to continually 
assess what FTD meant to their identity, and how they would use that understanding to 
seek control and increase self-esteem. One strategy people utilized was making 
downward social comparisons to find positive aspects of their identities (Taylor, 1983).  
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The study sample uniquely included individuals who had known their status for 
several years, which created the opportunity to hear from people in various stages of 
adaptation and therefore various phases of incorporating FTD into identity. Our results 
suggest that the impact of risk status on identity can fluctuate over time. Some 
individuals intentionally took action to alter the centrality of risk to their identity, 
whereas others evolved in their perceptions due to certain experiences or with more time 
to process. This identity reconstruction, part of the cycle of psychological adaptation, is 
an iterative process that differs for each person, although there may be some 
commonalities. In this study, participants who tended to take the “just a genetic carrier” 
stance were those who had known their status for at least one year, perhaps suggesting 
that this is an attitude that people may adopt over time as they adjust to their risk. 
However, there were some individuals who had known their status for several years who 
described immense anxiety and dread. Thus, how individuals reconstruct their identity in 
response to risk is nuanced, and is likely influenced by more factors than just time since 
learning results. There has been little work to date that considers how people adjust to 
this information over time or what this means to individuals’ sense of self. Better 
understanding of these processes may provide guidance about topics that need to be 
explored at clinical appointments with genetic counselors, neurologists, and other 
providers.  
Additionally, understanding these processes over time could shape interventions 
designed to bolster psychological adaptation through identifying common ways that 
people successful and unsuccessfully incorporate FTD into their identity. A few 
interventions have been developed to support self and identity in individuals with 
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dementia and were summarized by Caddell and Clare (2011). However, Caddell and 
Clare (2011) and Oyebode and Parveen (2019) assert that more research is needed in this 
area. Furthermore, none of these interventions were designed for presymptomatic 
individuals at risk of developing dementia. Perhaps some elements from existing 
interventions may be translated into interventions for those at risk of developing 
dementia, such as exploring and enhancing role-identities as in Cohen-Mansfield et al. 
(2006) or creating ways to physically represent one’s life history as in Massimi et al. 
(2008). However, many of the interventions described in Caddell and Clare (2011) focus 
on identity preservation through memory enhancement, which is not the core problem for 
presymptomatic individuals. Thus, research is needed to develop psychological 
interventions for individuals concerned with future loss of self with dementia, not just for 
those who are already symptomatic. 
Participants conceptualized their status in a variety of ways through constructing 
illness identity, the degree to which a chronic health condition is integrated into a 
person’s identity (Van Bulck et al., 2019). Some participants described illness identity 
stances that align with the existing constructs of enrichment, engulfment, acceptance, and 
rejection outlined by Van Bulck et al. (2019). Enrichment refers to feeling like a better 
person or having other positive impact from illness, engulfment refers to illness 
consuming identity, acceptance is when illness is incorporated as a piece of a larger 
identity, and rejection is dismissing the illness (Van Bulck et al., 2019). However, being 
at genetic risk for a condition without yet developing symptoms complicates this model 
of illness identity. Individuals who identified as “just genetic carriers” cannot be neatly 
categorized by the existing framework; they did not fully reject FTD as part of their 
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identity, but rather there was a temporal and symptom-based element to the incorporation 
of FTD into their identity. Another nuance not captured by the model arose from some at-
risk participants who called themselves patients. “Patienthood” describes when being a 
patient is a defining feature of identity (Sabat et al.,2011). The definition of patienthood 
seems to resemble that of engulfment, however, most participants that expressed this 
were not otherwise exhibiting engulfment attitudes. Since there does not currently exist a 
commonly known role for being asymptomatic but at-risk, individuals can only define 
themselves as “patients” or “care providers.” Thus, at-risk individuals may be trying to 
expand their own definition of “patient,” as this is a concrete role with which they can 
identify. Though patienthood has usually been considered a phenomenon that may 
increase marginalization and negative stereotyping of persons diagnosed, our data 
suggest that how this perception of patienthood influences at-risk individuals may be 
worth exploration. Additionally, some participants could be characterized as aligning 
with different illness identity constructs simultaneously or evolving in their stance over 
time. For example, some participants described both feeling like they were better people 
for being able to contribute to the research (enrichment) and feelings of doom, self-doubt, 
and fear (engulfment). Thus, while the illness identity model provides a useful framework 
for thinking about the data, it does not seem capable of capturing the complexities of the 
participants’ reconstruction of identity. 
Limitations 
The findings from this study are not intended to be representative of all 
individuals with known genetic risk for bvFTD. Our participants were well-educated, 
which often is associated with being of better financial standing. They may also have 
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been more savvy in identifying research, advocacy, and support opportunities and had the 
means to access these opportunities. Due to this, our participants may have had better 
access to counseling and other resources that helped them process what their status means 
to them. All participants in this study were Caucasian, which prevents consideration of 
how people from diverse backgrounds may experience this process differently. Many of 
the at-risk participants had the same gene implicated in their risk, C9ORF72. Pathogenic 
repeat expansions in this gene confer risk for both FTD and ALS, and therefore these 
participants may have differing experiences compared to those whose genetic risk is only 
for FTD. Participants were recruited from several sites, which introduces variation in the 
clinical care they received from genetic counselors and neurologists. How risk 
information is initially delivered may influence how people understand, perceive, 
incorporate and adjust to that risk (Fagerlin et al., 2011). Additionally, how the patient-
provider relationship is perceived may influence these processes (Roter, 2006). However, 
including individuals who are cared for by different providers allowed us to capture 
greater variety of reactions to clinical encounters. With increasing uptake of predictive 
genetic testing as well as increased awareness and better diagnostic clarity for FTD, more 
individuals are receiving risk information and at younger ages.  The reactions of younger 
individuals to risk may differ from the experiences represented by this sample and 
deserve consideration in the future.  
This study was only able to capture experiences of people willing to participate in 
the research study, and therefore our data are unlikely to represent the full range of 
experiences of those at risk of developing FTD. We did not capture the experiences of at-
risk persons who chose not to go through the testing process, as our inclusion criteria 
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required at-risk individuals to have undergone genetic testing with results conferring high 
risk of developing FTD. The experiences of individuals who do not know their status but 
know they are at risk based on family members’ diagnoses or testing results may differ 
from those included in this study sample. It should be acknowledged that the 
interpretation of the participants’ experiences is limited by the questions that were asked 
of them and is dependent upon the reflexivity of the primary researcher. However, the 
interviews were thorough and each participant was invited to discuss any uncaptured 
elements of their FTD experiences that felt important to share with the researcher. The 

















The experiences described by participants in this study have implications for the 
practice of clinical providers such as genetic counselors, geneticists, and neurologists. It 
is evident from this study that individuals experience a wide variety of emotional and 
behavioral responses to learning their genetic risk status for bvFTD. Clinical providers 
should be aware of the diverse ways that people may respond to their risk and normalize 
these experiences. These differing reactions and experiences shape how risk is 
incorporated into identity. Integration of FTD risk into identity evolves over time, 
bringing new challenges and threats for the individual who also evolves in his or her 
coping and management strategies. Providers should help at-risk individuals anticipate 
that how they conceptualize their risk may change subtly or drastically over time.  
Since individuals are continually processing what their risk means to them and 
facing new challenges, clinicians should continually assess and reassess individuals’ 
needs for support. Providers should also help individuals identify their strengths in facing 
such challenges and help them consider how they may apply these resources or strategies 
to combat future challenges. Referral to therapy should be made when individuals who 
are at risk for FTD may benefit from further exploration of what this information means 
to them as part of the psychological adaptation process. Genetic counselors and other 
providers should remain prepared to start these discussions and facilitate patients’ 
processing of the impact of identity restructuring. Most participants disclosed that 
discussing their experiences in detail as part of the interview was helpful, and many noted 
that they lacked opportunities to do so otherwise. Providers should invite these 
conversations during clinical appointments and make referrals to further counseling when 
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appropriate. This sentiment, as well as the finding that some individuals may have 
benefitted psychologically from medical surveillance, suggest the need for routine 
follow-up visits for presymptomatic individuals that include neurology assessments and 
genetic counseling. Currently, there is not a standard protocol regarding how often, when, 
and what follow-up should be offered to presymptomatic individuals after the initial 
genetic testing results disclosure. Many clinics follow the HD protocol (MacLeod et al., 
2013; HDSA, 2016) which recommends follow-up shortly after the initial results 
disclosure, however there is no standard recommendation for longitudinal follow up and 
often genetic counseling is not included in follow-up clinical appointments. In the 
continued absence of a standard protocol, clinics should set institution-based goals for 
presymptomatic neurology and genetic counseling follow-up based on available 
resources.   
Additionally, our findings showcase the importance of social roles in participants’ 
characterization of identity and the unique ways that FTD threatens such roles. Given 
this, genetic counselors and other providers should strive to include family members and 
other supportive individuals in counseling sessions. This family-systems based 
therapeutic approach has been described in Rolland’s work on the Family System Genetic 
Illness (FSGI) model, which considers the psychological and social challenges of genetic 
conditions for at-risk and diagnosed individuals as well as for their families, and how 
these changes differ based on disease typology and over the course of disease (Rolland 
and Williams, 2005). This approach may allow providers to better understand an at-risk 
person’s situation and needs, and may facilitate problem-solving for families. When 
appropriate, genetic counselors should consider referring families to longer term 
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counseling services grounded in this approach. Future research should assess the impact 
of this approach to determine the extent of its benefits for patients and families.  
Our results suggest that even individuals who seem to be coping well with their 
risk status in the present may have mildly impactful to nearly debilitating concerns about 
the future. Providers should explore how patients are dealing with uncertainty about the 
future. Interestingly, genetic counselors may need to pay special attention to individuals 
who adopt an “enriched” stance towards their risk status by declaring themselves a better 
person through the experience. People may adopt this attitude through positive coping 
mechanisms; however, it is also important to note that this may be reflective of defense 
mechanisms against feelings of shame (Kessler et al., 1984). Genetic counselors should 
be aware of this nuance, attend to comments that suggest an enriched stance with the co-
presence of shame, and be prepared to explore feelings of shame with their clients as 
appropriate.  
Uncertainty can be appraised positively, allowing room for hope, or may be 
appraised negatively, resulting in dread and fear depending on whether it is seen as a 
danger or an opportunity (Mishel, 1988). Genetic counselors and other providers should 
assess how at-risk individuals are thinking about the different elements of their lives that 
seem uncertain. They can then help at-risk clients by guiding them toward more effective 
coping strategies, helping them to redefine their goals, and helping them identify 
controllable aspects of life (Blesson and Cohen, 2019). Providers can also help their 
patients identify steps they can take to reach their goals and to gain more control (Blesson 
and Cohen, 2019). 
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With increasing hope in the neurogenetics field for gene-based and other therapies 
being developed in clinical trials, providers need to be aware of how this hope influences 
peoples’ conceptualizations of disease and willingness to participate in research. This 
population is desperate for a cure, and our results suggest that some people not only are 
driven to participate in the research effort but feel a sense of responsibility and even 
obligation to do so. Thus, genetic counselors, neurologists, and other providers need to 
ensure adequate counseling about the benefits and limitations of research protocols. 
These conversations should begin in pre-test genetic counseling, as hope for the ability to 
participate in research evidently is a motivating factor for some individuals to pursue 
genetic testing. Providers must delineate the differences between research and treatment, 
as well as ensure that people are given the information and support needed to make 
informed decisions. The state of the science and formidable nature of the disease render 
this population especially vulnerable to coercion. 
 Further research should extend this preliminary understanding of how persons at 
genetic risk for bvFTD incorporate the illness into their identity and experience the 
disease. Larger-scale, longitudinal, and quantitative studies of the affective and 
behavioral impact of risk information may allow for more specific guidance regarding 
what types of interventions at what times may be appropriate to support this population. 
Future studies should also attempt to capture the experiences of a more diverse group of 
individuals in terms of race, ethnicity, and education. With predictive testing occurring 
more often and at younger ages, exploration of experiences of younger individuals will 
also be important. Studies that consider identity and experience of individuals who are at 
familial risk prior to having genetic testing could be useful for comparison to experience 
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and identity following confirmed positive status. As hope in clinical trials continues to 
rise, research should be conducted to explore how this hope may be both beneficial and 
detrimental in individuals’ processing of their status.  
Additionally, all individuals in this study were eager to contribute to the research 
efforts and most incorporated this as a positive part of their FTD identity. Research 
participation was part of the core motivation for pursuing genetic testing for several study 
participants, which aligns with reasons for testing outlined in other studies of ALS and 
FTD genetic testing (Steinbart et al., 2001; Crook et al., 2017). Many participants felt 
they benefitted from participation in this study; they disclosed that this study allowed 
them to discuss things that they otherwise would not have the chance to discuss, and that 
helping others through research made them feel good. Such experiences are not unique to 
participants in this study. Lakeman et al. (2013) argued that participating in qualitative 
research that allows for telling personal stories can itself be therapeutic, as it can help 
participants to make sense of their experience (Lakeman et al., 2013). Research 
participation may also provide at-risk persons with a sense of control, purpose and a 
clearly defined role in a time when much is uncertain. However, research will not be 
something that all at-risk individuals choose to pursue and not all will personally benefit. 
Regardless, clinicians should identify opportunities for at-risk individuals to contribute to 
research efforts and help at-risk individuals navigate the risks and benefits of 
participation when appropriate. All individuals should be informed of the existing 
opportunities as our data suggest that this can be a powerful source of hope and provide a 




Appendix I: Consent Documents 
Verbal Consent Script 
University of Pennsylvania 
ADULT ORAL CONSENT SCRIPT 
 
Study Title:  VOICE Of bvFTD [Voices Of Individuals: Challenges and Experiences Of bvFTD] 
Principal Investigator:  Murray Grossman, MDCM, EdD 
PI Version Date:  Version 1, Date 5 June 2019 
 
Hello, is this [name of participant]? My name is Laynie Dratch. I am a graduate student 
from Johns Hopkins. I am working on a research project for my master’s thesis. You 
gave (provider or researcher or me) from (site name) permission for us to contact you 
about our research. (The provider or researcher or I) also sent you a packet of forms. I 
would like to tell you a bit more about our research project because you may be able to 
participate. Are you interested in hearing about my study and what your participation 
would involve?  Do you have time to talk to me now? Are you in a place that feels safe to 
talk to me about this project? 
 
[If not interested]: Okay, thank you for your time. Have a great day! 
[If not in a safe place or now is not a good time]: Okay, when is a good time for me to 
call you back when you will have time to talk in a safe and private place? 
[If yes]: Great! I’m happy you are interested in hearing more.  
 
Key Information Summary  
We are asking you to volunteer for a research study about life with or at risk for 
behavioral variant frontotemporal dementia. I will call it bvFTD for short. We want to 
learn how bvFTD impacts your day to day life, how you think about yourself, and what 
challenges you face. This is an interview study. We are asking you if you want to be in 
this study because you may be eligible to join as a person who is living with or at risk for 
bvFTD. You do not have to join this study. It is your choice whether you want to join or 
not. There is no penalty for not joining. In the next few minutes, we will talk about the 
details of the study, what we would ask you to do if you join, and the potential risks and 
benefits of being in the study. You can ask as many questions as you need to help make 
your decision.  
 
What is the purpose of this research? 
The study is run by Johns Hopkins University, the National Institutes of Health, and the 
University of Pennsylvania. The goal of our study is to learn more about experiences of 
living with, or at risk for developing bvFTD. We want to understand how bvFTD affects 
your day to day life, how you think about yourself, and how you overcome challenges. 
The study will involve interviews to help us learn as much as possible about living with 
bvFTD. We hope that this will guide future research, resource development, and clinical 
practice. We are planning on interviewing about 30 people who either have bvFTD, or 
have had genetic testing that showed they are at risk of developing bvFTD.  
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Why are you being asked to participate? 
We are asking you to join our study because [you or your provider or your researcher] 
thought that you might qualify for the study. You might be able to join the study for one 
of two reasons. You might be able to join if you are a person with bvFTD and your 
symptoms started at least two months ago. Or, you might be able to join if you are a 
person who has had genetic testing results that showed high risk of developing bvFTD 
and you learned about the results at least two months ago. 
 
What would you be asked to do if you join the study? 
If you want to take part in the study, you will have at least two phone calls from us. This 
is one of those phone calls. During this phone call, which will take about 15 to 20 
minutes, we will review the study in detail together. We will ask you some basic 
questions about yourself and your understanding of the study as part of the consent 
process, and to make sure that you are eligible for the study. We cannot include every 
interested person, so we want to make sure that each person we include is a good 
candidate for the project. 
 
If you are a good match for the project based on the conversation we have today, then we 
will schedule another phone call. During that next call, we will ask you a few more 
questions about your thinking, and we will also complete the interview. The questions we 
ask you to assess your thinking are not going to be used for any diagnostic purpose. The 
interview questions will be about living with or at risk for bvFTD. I will be the person 
that you interview with if you participate. The interview will last about 30 to 60 minutes. 
When I call you for the interview, I will make sure that you are in a location that feels 
comfortable and private before starting the interview, just like I did today. We 
recommend that you avoid public spaces during your phone interview. The best place to 
do the interview is somewhere private and quiet. I will be in private room during the 
interview, like I am now during this phone call. We will audio record the interview. We 
will give you a $20 gift card to thank you for your time if you participate in this interview 
study. This gift card will be sent to you after your interview.   
 
It is your decision whether or not you want to join our study. You do not have to join if it 
sounds like something you do not want to do. You may also choose to join now, but stop 
before the study is finished. There will be no penalty if you decide not to join, and there 
will be no penalty if you stop the study early. It will not impact any of your medical care. 
If you participate in the interview but want to stop early, you may still receive the $20 
gift card. 
 
What questions do you have so far? 
 
What are the potential risks of the study? 
There are no physical or medical procedures included in this study. This means that there 
is no risk of physical harm. You might become sad, anxious, or frustrated when 
answering some of the questions about your life with bvFTD. If there are questions that 
you do not want to answer, you do not have to answer them. You can also stop the 
interview completely at any time. If you become very upset during the interview, we will 
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suggest that you contact your provider. Or, if you are upset and do not want to talk to 
your provider, we can help you find someone else to talk to. If talking about your 
experiences makes you think of questions about bvFTD, we will refer you to someone 
who may be able to answer your questions. The other potential risk of the study is related 
to privacy and confidentiality. This is risk related to other people learning about your 
diagnosis. The research team does a lot to reduce these risks. We will talk about this more 
in a minute. You can also reduce the risk of people learning about your diagnosis by 
doing the interview in a private place. 
 
What are the potential benefits of the study? 
We do not expect you to personally benefit from the study. You might appreciate having 
the chance to talk about your experiences with bvFTD. You will not receive any 
treatments as part of this study. Even though you might not benefit directly from this 
study, you will help us learn more about the experiences of life with bvFTD. We may be 
able to use what we learn from you and other participants to improve resources and care 
for people with bvFTD in the future.  
 
What will happen with the information I share? 
There is a risk that someone outside the study will see your information. We will do our 
best to keep your information safe by using a participant ID number, removing the names 
of people and places from your interview data, and storing all information in secure ways 
– either locked in filing cabinets, or in a password-protected file on an encrypted 
computer. Let’s talk about this in a bit more detail and explain what that means. 
 
If you join the study, we will give you a participant ID number. This number will be used 
to label all of your study information. This way, the only information that connects your 
name to your study information is a password-protected file that includes the link 
between your name and your participant number. Only I will have access to this protected 
file. After your interview, we will destroy the link that connects your participant ID 
number to your name and contact information. 
 
The interview will be audio-recorded and later transcribed. This means that a professional 
company will turn the audio into written text. The company will remove the names of any 
people and places that we say in the interview. This way, we can talk about people and 
places during the interview without having to worry about their information being 
included in our research. Once we have checked that the written version of the interview 
matches the audio recording of the interview, we will destroy the audio recording. This 
means that only the written version will be left, and this written version will not include 
any names of people or places. This written version is what we will use for data analysis, 
and for any papers that we write. If other researchers want access to our data, they also 
will only have access to this written version that does not have your name or the name of 
any person or place we talked about. 
 
After we finish your interview process and send you your $20 gift card, we will destroy 
your name and other personal information including your contact information. At the end 
of the interview, we will ask if you would like to know about the results of the study. If 
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you would like us to send you an overview of the results, we will ask for your permission 
to keep your contact information in a separate, protected document. 
 
Who do I contact with questions or concerns? 
You may contact the VOICE of bvFTD team with any questions or problems with this 
research. Contact the University of Pennsylvania IRB Office if you have questions about 
your rights as a participant of this study, or if you feel you have not been treated fairly.  
The contact information is on the written version of the consent form that we are 
reviewing. This was sent to you in the packet you received.  
 
Please reach out to one of these resources if you have questions or concerns: 
 
Researchers’ Contact Information: 
 
Laynie Dratch, BA 
Student Investigator / Associate 
Investigator 






Murray Grossman, MDCM, EdD 
Principal Investigator 




Lori Erby, PhD, ScM, CGC 
Primary Associate Investigator 
Medical Genomics / Metabolic Genetics 
Branch 




University of Pennsylvania 
Philadelphia, PA 
Office of Regulatory Affairs Phone: 
215-898-2614 
IRB Phone: 215-573-2540 
 
Do you have any questions?  [Probe to assess the participant’s understanding.] 
 
Are you interested in joining the study? 
 
[if no]: Okay. Thank you for your time. Have a great day! 
[if yes]: Great! Like I mentioned before, we cannot take every person who is interested in 
the study. I would like to ask you a few questions to make sure you are a good fit for the 
study. Some questions will check to make sure that you understand the study, and some 
questions will ask for basic information about yourself and your family from the 
demographics form that you received earlier. Is it okay for me to ask you these questions 
now? 
 
[If no]: Okay, when is a good time for me to call you back?   [If yes]: Thank 
you. 
 
[Complete Informed Consent Comprehension Assessment] 
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[Ask for Demographic Information] 
 
[If eligible for interview]: Thank you for answering all of these questions. Based on what 
you have told me, you are a good match for the study. Let’s go ahead and schedule the 
interview now. 
 
Some people think it helps to think about their experiences with FTD before the 
interview. If you want to write or think about your experiences with FTD, you can do that 
between now and the interview.  For example, you could think about what it felt like to 
get the [diagnosis or test result]. Do you have any questions for me? I look forward to our 
phone interview on (date /time scheduled). Thank you!   
 
[If not eligible for interview]: Thank you for answering all of these questions. 
Unfortunately, we are not able to accept everyone into the study. Based on our 
conversation, you are not the best match for this study, and we cannot include you in the 
study at this time. The rest of the research team and I really appreciate the time that you 
have spent engaging with us. We hope that we might be able to offer more studies in the 
future. We want to thank you for your interest in our work and for your time. Do you 


















Consent Information Sheet  
University of Pennsylvania 
CONSENT INFORMATION 
 
Study Title:  VOICE Of bvFTD [Voices Of Individuals: Challenges and Experiences Of bvFTD] 
Principal Investigator: Murray Grossman, MDCM, EdD   Student Investigator: Laynie Dratch    
PI Version Date:  Version 1, Date 5 June 2019 
 
Key Information Summary  
We are asking you to volunteer for a research study about life with or at risk for 
behavioral variant frontotemporal dementia (bvFTD). We want to learn how bvFTD 
impacts your day to day life, how you think about yourself, and what challenges you face. 
This is an interview study. We are asking you if you want to be in this study because you 
may be eligible to join as a person who is living with or at risk for bvFTD. You do not 
have to join this study. It is your choice whether you want to join or not. There is no 
penalty for not joining. This form includes details of the study, what we would ask you to 
do if you join, and the potential risks and benefits of being in the study. You can ask as 
many questions as you need to help make your decision.  
 
What is the purpose of this research? 
The study is run by Johns Hopkins University, the National Institutes of Health, and the 
University of Pennsylvania. The goal of our study is to learn more about experiences of 
living with, or at risk for developing bvFTD. We want to understand how bvFTD affects 
your day to day life, how you think about yourself, and how you overcome challenges. 
The study will involve interviews to help us learn as much as possible about living with 
bvFTD. We hope that this will guide future research, resource development, and clinical 
practice. We are planning on interviewing about 30 people who either have bvFTD, or 
have had genetic testing that showed they are at risk of developing bvFTD.  
 
Why are you being asked to participate? 
We are asking you to join our study because you might qualify for the study. You might 
be able to join the study for one of two reasons. You might be able to join if you are a 
person with bvFTD and your symptoms started at least two months ago. Or, you might be 
able to join if you are a person who has had genetic testing results that showed high risk 
of developing bvFTD and you learned about the results at least two months ago. 
 
What would you be asked to do if you join the study? 
If you want to take part in the study, you will have at least two phone calls from us. 
During the first phone call, which will take about 15 to 20 minutes, we will review the 
study in detail together. We will ask you some basic questions about yourself and your 
understanding of the study as part of the consent process, and to make sure that you are 
eligible for the study. We cannot include every interested person, so we want to make 
sure that each person we include is a good candidate for the project. If you are a good 
match for the project based on that conversation, then we will schedule another phone 
call. During that next call, we will ask you a few more questions about your thinking, and 
we will also complete the interview. The questions we ask you to assess your thinking are 
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not going to be used for any diagnostic purpose. The interview questions will be about 
living with or at risk for bvFTD. Laynie Dratch will be the person that you interview with 
if you participate. The interview will last about 30 to 60 minutes. When Laynie calls you 
for the interview, she will make sure that you are in a location that feels comfortable and 
private before starting the interview. We recommend that you avoid public spaces during 
your phone interview. The best place to do the interview is somewhere private and quiet. 
Laynie will be in private room during the interview. We will audio record the interview. 
We will give you a $20 gift card to thank you for your time if you participate in this 
interview study. This gift card will be sent to you after your interview.   
 
It is your decision whether or not you want to join our study. You do not have to join if it 
sounds like something you do not want to do. You may also choose to join now, but stop 
before the study is finished. There will be no penalty if you decide not to join, and there 
will be no penalty if you stop the study early. It will not impact any of your medical care. 
If you participate in the interview but want to stop early, you may still receive the $20 
gift card. 
 
What are the potential risks of the study? 
There are no physical or medical procedures included in this study. This means that there 
is no risk of physical harm. You might become sad, anxious, or frustrated when 
answering some of the questions about your life with bvFTD. If there are questions that 
you do not want to answer, you do not have to answer them. You can also stop the 
interview completely at any time. If you become very upset during the interview, we will 
suggest that you contact your provider. Or, if you are upset and do not want to talk to 
your provider, we can help you find someone else to talk to. If talking about your 
experiences makes you think of questions about bvFTD, we will refer you to someone 
who may be able to answer your questions. The other potential risk of the study is related 
to privacy and confidentiality. This is risk related to other people learning about your 
diagnosis. The research team does a lot to reduce these risks. We will talk about this more 
in a minute. You can also reduce the risk of people learning about your diagnosis by 
doing the interview in a private place. 
 
What are the potential benefits of the study? 
We do not expect you to personally benefit from the study. You might appreciate having 
the chance to talk about your experiences with bvFTD. You will not receive any 
treatments as part of this study. Even though you might not benefit directly from this 
study, you will help us learn more about the experiences of life with bvFTD. We may be 
able to use what we learn from you and other participants to improve resources and care 
for people with bvFTD in the future.  
 
What will happen with the information I share? 
There is a risk that someone outside the study will see your information. We will do our 
best to keep your information safe by using a participant ID number, removing the names 
of people and places from your interview data, and storing all information in secure ways 
– either locked in filing cabinets, or in a password-protected file on an encrypted 
computer.  
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If you join the study, we will give you a participant ID number. This number will be used 
to label all of your study information. This way, the only information that connects your 
name to your study information is a password-protected file that includes the link 
between your name and your participant number. Only Laynie will have access to this 
protected file. After your interview, we will destroy the link that connects your 
participant ID number to your name and contact information.  
 
The interview will be audio-recorded and later transcribed. This means that a professional 
company will turn the audio into written text. The company will remove the names of any 
people and places that we say in the interview. This way, we can talk about people and 
places during the interview without having to worry about their information being 
included in our research. Once we have checked that the written version of the interview 
matches the audio recording of the interview, we will destroy the audio recording. This 
means that only the written version will be left, and this written version will not include 
any names of people or places. This written version is what we will use for data analysis, 
and for any papers that we write. If other researchers want access to our data, they also 
will only have access to this written version that does not have your name or the name of 
any person or place we talked about. 
 
After we finish your interview process and send you your $20 gift card, we will destroy 
your name and other personal information including your contact information. At the end 
of the interview, we will ask if you would like to know about the results of the study. If 
you would like us to send you an overview of the results, we will ask for your permission 
to keep your contact information in a separate, protected document. 
 
Who do I contact with questions or concerns? 
You may contact the VOICE of bvFTD team with any questions or problems with this 
research. Contact the University of Pennsylvania IRB Office if you have questions about 
your rights as a participant of this study, or if you feel you have not been treated fairly.   
 
Please reach out to one of these resources if you have questions or concerns: 
 
Laynie Dratch, BA 
Student Investigator / Associate 
Investigator 






Murray Grossman, MDCM, EdD 
Principal Investigator 




Lori Erby, PhD, ScM, CGC 
Primary Associate Investigator 
Medical Genomics / Metabolic Genetics 
Branch 




University of Pennsylvania 
Philadelphia, PA 




*Note: The consent forms and information sheets included in this document are those 
from the University of Pennsylvania. Parallel versions of these consent forms with Johns 



































Consent Comprehension Assessment 
Informed Consent Comprehension Assessment 
 
Participant type: Individual with bvFTD  Individual at risk for bvFTD  
 
Now I am going to ask you some questions on the consent form we just reviewed together. It’s 
important that all participants understand the study. 
 
1. Explain to me what this study is about. Can you tell me why this study is being done? 
 
Sufficient  Questionable  Insufficient 
 
2. What will you be asked to do if you enroll in the study?  
 
Sufficient   Questionable   Insufficient 
 
3. Are there risks to you of being in the study? What are the risks?  
 
Sufficient   Questionable   Insufficient 
 
4. Is there a chance you will benefit from being in the study? How might you benefit? 
 
Sufficient   Questionable   Insufficient 
 
5. Will this study impact your clinical care? 
 
Sufficient   Questionable   Insufficient 
 
6. What do you think about being part of a study that is designed to help others? 
 
Sufficient   Questionable   Insufficient 
 
7. Who’s decision is it whether you enroll in the study? Can you say no? Would any bad things 
happen if you said no? How would you let the investigator know if you wanted to stop? 
 
Sufficient   Questionable   Insufficient 
 
Determination:  Able to Consent  Not Able to Consent  
 
Interviewer will repeat sections of consent form for any assessment question responses deemed 
questionable or insufficient; targeted education may be used to improve potential subjects’ 
understanding. A final determination that an individual is able to consent requires that the 
individual is found sufficient on all necessary items. 
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Appendix II: Assessments 
Demographics Questionnaire 
Demographics Survey 
1. What is your current age? _______________  
2. What is your gender? Please circle your response. 
Male     Female   Other ________________ 
3. What is your race? Please circle your response. 
1. White/Caucasian  
2. Black/African American  
3. American Indian/Alaska Native  
4. Asian/Pacific Islander 
5. Other ________________________ 
4. What is your ethnicity? Please circle your response. 
 1. Hispanic/Latino 
 2. Non-Hispanic/Latino 
5. What is your marital status? Please circle your response. 
 1. Married 
 2. Divorced 
 3. Widowed 
 4. Single 
 5. Other __________________________ 
6. How many biological children do you have? _____________________   
7. Do you have any other dependents (ex: adopted children)?      Yes (how many?) ____     No 
8. What is the highest level of education that you have completed? Please circle your 
response. 
1. Less than high school 
 2. High school graduate 
 3. Some college 
 4. College graduate 
 5. Graduate degree  
9. What is your most recent past or current occupation?  _____________________________  
10. How would you describe your current employment status? Please circle your response. 
1. Employed, Full-Time 
2. Employed, Part-Time 
3. Unemployed 
4. Retired  
5. Other _________________________ 
11. At what age were you formally diagnosed with FTD? __________  OR circle: Not 
Applicable 
12. At what age were you first diagnosed with dementia? __________ OR circle: Not 
Applicable      
13. At what age did your symptoms of FTD begin? ______________  OR circle: Not 
Applicable 
14. Have you had genetic testing for FTD? Please circle your response. 
1. Yes 
2. No 
3. I’m not sure 
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15. If you have had genetic testing, what was the result? Please circle your response. 
 1. Showed that I have FTD (positive result) 
 2. Did not show that I have FTD (negative result) 
 3. I am not sure what the test found 
 4. Not applicable, I did not have genetic testing 
 5. I do not know/remember if I have had genetic testing 
16. If you had genetic testing that showed that you have FTD (a positive result), do you 
recall which gene the change was found in?  Yes [If so, which one(s)]_______    No      
 Not Applicable 
 
17. At what age did you learn the results of your FTD genetic testing? OR circle: Not 
Applicable      
 
18. How many of your family members have had any type of dementia? _________________  
19. Which family members have had any type of dementia? Circle all that apply. 
1. Parent    2. Child     3. Sibling    4. Aunt/Uncle    5. Cousin    6. Grandparent    7. Other 8. None 
 
20. How many of your family members have had FTD? ____________________________  
 
21. How many of your family members have had Amyotrophic Lateral Sclerosis (ALS or 
Lou Gehrig’s) or a combination of FTD/ALS?  ___________________________ 
 
22. Which family members have had FTD or FTD/ALS? Circle all that apply. 
1. Parent    2. Child     3. Sibling    4. Aunt/Uncle    5. Cousin    6. Grandparent    7. Other 8. None 
 
23. How many close friends do you have with any type of dementia? ____________________  
 
24. Do you have any other medical conditions that impact your daily life? 
Yes (If so, please describe) ___________________________________________  No 
 
25. Please tell us how sure YOU are about whether or not you currently have symptoms of 
FTD. Please circle the number that YOU feel best represents your experience. For example, 
select “0” if you are sure that you have not had any bvFTD symptoms, “4” if you are sure 
that you have had symptoms, or somewhere in between if you are not certain about whether 
you have had symptoms. 
 




26. Please tell us how sure YOUR DOCTOR is about whether or not you currently have 
symptoms of FTD. Please circle the number that you think YOUR DOCTOR feels best 
represents your experience. For example, select “0” if your doctor is sure that you have not 
had any bvFTD symptoms, “4” if your doctor is sure that you have had symptoms, or 
somewhere in between if your doctor is not certain about whether you have had symptoms.  
 
No   Symptoms                  Symptoms 
 
0 1 2 3 4 




REVISED TELEPHONE COGNITIVE SCREEN (T-CogS) 
Participant ID Number: _______________                        Date of interview: ________________ 
Award 1 point for each correct response. Award 0 points for each incorrect response. Mark the total points 
per question to the left of the numbered item.                                                                                                                                        
ORIENTATION:                                                                                                         
25.  What is the year?_____________ 
26.  What season of the year is it? _____________  
(During March, winter or spring is acceptable; during June, spring or summer is acceptable; 
during September, summer, fall, or autumn is acceptable; during December, fall, autumn, or 
winter is acceptable). 
27.  What is the date or day of the month? (+/- 1 date is acceptable)_____________ 
28.  What is the day of the week?_____________ 
29.  What is the month?_____________ 
30.  Can you tell me where you are right now? For instance, what state are you in?_______ 
31.  What county are you in?______________ 
32.  What city/town are you in? _____________ 
33.  IF IN A PRIVATE HOUSEHOLD, ASK: 
       What is the address you are at?________________________ 
 Correct street name and house number must be given.   
  Zip code is not necessary for a correct response.               
       OR  
   IF INSTITUTIONALIZED, ASK: 
What is the name of the place where you are staying?__________________ 
  Name of institution must be given to receive credit.           
34.  What is your telephone number (there/at home or where you usually  
 can be reached)?_____________ 
REGISTRATION: 
35.  I am going to name three objects.  After I have said them, I want you to repeat them. 
Remember what they are because I am going to ask you to name them again in a few minutes.  
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The three objects are: “Apple”, “Table”, and “Penny”. Could you repeat the three objects for me? 
The words should be read at a rate of 1 per second, speaking clearly and audibly. You are 
allowed to read the words only once before scoring. 
 Score on first trial 
     Apple __________   Table __________  Penny __________                              
          Repeat the three words until:  
1) the subject correctly repeats all three or   
      2) 3 total trials have been presented (including initial presentation).         
                                      
      Number of trials:___________ 
ATTENTION: 
 
36. Now, I am going to give you a word and ask you to spell it forwards and backwards. The 
word is WORLD.  Spell WORLD forwards.     
 (If the subject is unable to spell the word, spell it out loud, and ask the subject to repeat 
the spelling.  Continue until it has been spelled successfully or until you have spelled it to the 
subject three times.     
                
                               Now spell the word WORLD backwards:  ___   ___   ___   ___   ___                                                    
                                                             D      L      R       O     W 
 
  Score 5 points for a correct sequence.  Count 1 error for each omission, letter 
transposition (switching  adjacent letters), insertion (inserting a new letter), or misplacement 
(moving W,O,R,L,D by more than one space).     
RECALL: 
 
37.  Now, what were the 3 objects I asked you to remember?   
  (This should be administered as soon as the “world backwards” item is completed. 
Cueing is allowed if the subject is not able to recall words, but credit is not given for any word 
recalled after a cue).   
    




38.  I would like you to repeat a phrase after me exactly as I say it.  The phrase is: “No ifs, ands, 
or buts”.   
It is very important to speak loudly and enunciate clearly as you read this phrase.  One repetition 
of the phrase is permissible if it is clear that the phrase was not adequately heard. Otherwise, 
repetition is not allowed.    
39.  Tell me, what is the thing called that you are speaking into as you talk to me?  
     Correct: Telephone, Cell Phone, Hand-held, Mobile Device, etc… 
 
40.  Now I’d like you to do these three things. Say hello, tap the phone to a table 3 times, then say 
I’m back. 
  Hello_____ Tap 3 times_____  I’m back_____ 
  
 
Total Score (26 Max):__________                                
Comments: 
 
*Revised appendix for: Newkirk LA, Kim JM, Thompson JM, et al. Validation of a 26-Point 
Telephone Version of the Mini-Mental State Examination. J Geriatr Psychiatry Neurol 2004; 
17(2): 81-7. 
Bottom Row Corrected 1/11/2005. Items 39 and 40 revised 2018 to match current telephone 












Revised Table of In-Person and Telephone Cognitive Screen Conversions  


















Cognitive Screen Score 
0 0 0 6 
1 0 1 7 
2 0 2 8 
3 0 3 9 
4 1 4 10 
5 2 5 10 
6 3 6 11 
7 4 7 12 
8 5 8 13 
9 6 9 13 
10 7 10 14 
11 8 11 15 
12 9 12 16 
13 10 13 16 
14 11 14 17 
15 12 15 18 
16 13 16 19 
17 14 17 20 
18 15 18 20 
19 16 19 21 
20 17 20 22 
21 18 21 23 
22 19 22 23 
23 20 23 24 
24 21 24 25 
25 22 25 26 
26 23 26 27 
27 24   
28 25   
29 26   





Immediately following the completion of the T-CogS, participants will be asked the 
following. 
 





2. The highest score you can get for answering all of the questions I just asked you 
correctly is a 26. The lowest score for answering none of the questions correctly is a zero. 





Question 1: Compare to LD’s assessment of performance written in comments about the 
T-CogS, and MMSE categorization of the numerical value (ex: cognitively normal, mild 




Question 2:  Record the discrepancy between the actual score and the participant’s guess 





Appendix III: Interview Materials 
At-Risk Interview Guide 
Interview Guide – Presymptomatic 
Hello. This is Laynie Dratch from Johns Hopkins. I’m calling for (name of participant) 
for our scheduled interview. Am I speaking with (name of participant)? 
 
Are there people around you right now? Do you feel okay talking to me? Is anyone with 
you during this interview? Are you at home or in another location? 
 
Before we begin the interview, I would like to ask you a few questions that I ask every 
participant to assess your thinking. Is this okay with you? 
 
[Perform T-CogS and Insight Probe] 
 
Thank you for answering those questions. Now we can begin the interview. I want to 
remind you that if you are not comfortable answering a question, you do not have to 
answer it. You may also ask for a break or stop the interview completely at any time. Do 
you have any questions? I want to make sure you are in a comfortable place before 
starting the interview. Do you feel okay talking to me where you are?  
 
Self-Assessment: 
The goal of the study is to learn about the experiences of bvFTD. We are 
interviewing people who have symptoms of bvFTD, and people who do not yet have 
symptoms. Which category do you feel like you belong in: someone with or without 
symptoms? 
 
Okay, thank you. Because the study is about FTD, most of the questions will focus on 
your FTD experiences. But, the research team recognizes that you are a person with 
other life experiences, and you are more than just your FTD. Let’s talk first about your 
life beyond FTD.  
 
Tell me about yourself. If you were meeting someone for the first time, what would 
you want someone to know about who you are? 
• About your personality? 
• About your career and other responsibilities? 
• About what you like to do for fun? Your hobbies or activities that you do? 
• About your relationships with your family and friends? 
 
Thank you. Now that I have learned a little about you as a person, I will ask you some 




What brought you to the [FTD clinic OR research study OR support group]? 
 
Please tell me about the onset of [family member’s] FTD.  
• When and how did [family member’s] symptoms begin?  
• Who first noticed the symptoms?  
• What symptoms did you notice?  
• What thoughts went through your head when you started noticing symptoms? 
• How would you describe how you were feeling at that time? 
 
Please tell me about the genetic testing process. 
• What made you decide to get the testing? 
• What were you expecting the results to be? 
• How did you feel between when you had the testing and when the results came 
back? 
• How did it feel when the results came back? What went through your mind? 
 
What has it meant to you to learn about the genetic/inherited nature of FTD?  
• What, if anything, has it changed for you? For your family? 
 
Tell me about how things have changed for you since you learned about your 
results.  
• What are some of the biggest changes in terms of [relationships with people, 
outlook on life, daily activities]?  
• How has the knowledge of risk of developing symptoms affected your life? 
o Physical symptoms? Behavioral symptoms? Cognitive symptoms? 
Emotional symptoms? Changed personality? 
o Tell me about a time when anticipating [mentioned symptom] has affected 
your life. 
o How have the potential for these symptoms affected your career? The 
activities you enjoy doing? Who you spend time with? 
 
What have you been told about your risk of developing symptoms from [name of FTD 
provider]?  
• What are your reactions to that information?  
• How does it fit with how you thought or felt about your risk?  
 
Personhood, Appearance to Self and to Others, Identity 
You’ve told me about how [changes above] have changed for you. Besides these 
changes, how has FTD changed the way that you think about yourself? 
• The way you feel about yourself? 
 
Tell me about a time when you told someone about your FTD risk. What was it like? 
How did they react? How did you feel?  
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What changes, if any, have you noticed with your relationships with people close to 
you (care partner, family, friends, etc.)?  
• What changes, if any, have you noticed in the way people treat you? 
o In the way people talk to you? 
• What changes, if any, have you noticed in the way you treat other people? 
Many people at risk of developing FTD have experiences or interactions with others 
that stand out to them because they were especially positive or especially negative.  
• Tell me about a time when someone made you feel bad about yourself. 
o What do you worry about when you interact with other people? 
• Tell me about a time when someone made you feel good about yourself. 
o What do people do that makes you feel valued? Accepted? Understood? 
 
Tell me about an important decision that you had to make recently. How satisfied 
are you with how much you got to decide for yourself? How do you feel about 
whether other people listened to what you had to say? 
• Tell me about a medical decision that had to be made. What was your role in 
making the decision? In participating in the appointment?  
• Tell me about a time when you had to decide about an activity. What was your 
role in making the decision? [employment, hobbies, driving] 
• Who helps you with decision making? How do they help? How do they include 
you? Please give me an example of a time someone helped you make a decision. 
• To what extent do you feel like other people understand you? 
 
How has FTD changed your sense of independence?  
• How do [potential] changes in your employment impact your sense of 
independence? 
o How have financial changes contributed? 
• How do [potential] changes in your driving relate to your sense of independence? 
 
What do you think [care partner, friends, family] would say about how your FTD results 
have affected you? 
• How would your [care partner, friends, family] say you have changed as a person 
since your testing?  
• What do you think [care partner, friends, family] would say are your biggest 
challenges? 
• How do you think your [care partner, friends, family] would say your results have 
positively impacted you?  
 
Coping and Management: Facing Challenges, Finding Successes 
What is a bad day for you like? What are the biggest challenges about living with 
your risk?  
• What is hardest for you, and why? What do you wish you could do but cannot?  
• What feelings does this bring up for you? 
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What strategies do you use to manage [any of the challenges mentioned above]?  
• What are things that you do that help make [above challenges] less challenging? 
 
What is a good day for you like? What are the most important things that you have 
learned from living with your FTD risk? 
Who helps you with your FTD risk? With emotional support? With physical things? 
With appointments?  
 
How do you get support?  
• Who do you go to when things get tough? Who do you talk to about your 
challenges? How does this [person or provider or organization] help you?  
• What is good about getting support this way? What is bad about it?  
 
How do you feel about the amount of support you are getting?  
• Tell me about a time when you wish that you had more support. 
 
We talked earlier about your initial thoughts and feelings about the genetic testing 
results. We’ve also talked about how you are thinking and feeling about them now. 
Tell me about how you have gotten from your initial reactions to where you are 
now. What has helped with that? What has made it difficult?  
 
How have you dealt with stressful situations in the past? Is that different from how you 
deal with stress now? If so, how? 
 
Future Orientation 
What do you think life will be like for you in the next year? In the next five years? 
How might it be different from your life now? 
 
What worries do you have about the future? What challenges do you think you will 
face? 
 
What are your expectations, hopes, and dreams? How have those changed over time? 
 
 
Mental Health  
Some people living with risk of FTD experience depression. Tell me about your 
experiences with that. 
 





What do you think is most important for other people to understand about living at 
risk of FTD?  
• What is the most important thing for a [a health care provider, care partner, family 
member, friend, colleague] to understand?  
• What would you say to another person who was just given testing results that 
showed high risk of FTD? What advice would you give them? 
I’d like to ask you to be part of my research team for these next few questions. 
Imagine you are now the person in charge of an interview, and the person you are 
interviewing was recently given testing results that show high risk of developing 
FTD.  
• What questions would you ask them? What would you want to know about 
their experience? What do you think would be important to know about 
them? 
 
Is there anything that you think I should have asked you but didn’t?  
• Is there anything that we didn’t talk about that you feel is important and you 
would like to share? 
 
How do you feel about being in this study? 
 
We are now at the end of our interview. The rest of the research team and I know that 
sharing your experience of living at risk for FTD can be difficult and emotional. We want 
you to know how much we value your responses and hearing your story. Thank you for 
your time and for your answers. Do you have any questions, comments or final thoughts? 
 
Thank you for completing the interview. I will send you the $20 gift card soon.  
 
Would you like me to send you a summary of the results when I finish the project?  
[if yes] Great. I will need to keep your contact information to be able to send you 
the results. Your contact information will not be linked to any other study 
information. Is this okay with you? 
 
 [if no] Okay. I will go ahead and remove your contact information from the study 
database after I mail your gift card. 
 






Diagnosed Interview Guide 
Interview Guide – Symptomatic 
 
Hello. This is Laynie Dratch from Johns Hopkins. I’m calling for (name of participant) 
for our scheduled interview. Am I speaking with (name of participant)? 
 
Are there people around you right now? Do you feel okay talking to me? Is anyone with 
you during this interview? Are you at home or in another location? 
 
Before we begin the interview, I would like to ask you a few questions that I ask every 
participant to assess your thinking. Is this okay with you? 
 
[Perform T-CogS and Insight Probe] 
 
Thank you for answering those questions. Now we can begin the interview. I want to 
remind you that if you are not comfortable answering a question, you do not have to 
answer it. You may also ask for a break or stop the interview completely at any time. Do 
you have any questions? I want to make sure you are in a comfortable place before 
starting the interview. Do you feel okay talking to me where you are?  
 
Self-Assessment: 
The goal of the study is to learn about the experiences of bvFTD. We are 
interviewing people who have symptoms of bvFTD, and people who do not yet have 
symptoms. Which category do you feel like you belong in: someone with or without 
symptoms? 
 
Okay, thank you. Because the study is about FTD, most of the questions will focus on 
your FTD experiences. But, the research team recognizes that you are a person with 
other life experiences, and you are more than just your FTD. Let’s talk first about your 
life beyond FTD.  
 
Tell me about yourself. If you were meeting someone for the first time, what would 
you want someone to know about who you are? 
• About your personality? 
• About your career and other responsibilities? 
• About what you like to do for fun? Your hobbies or activities that you do? 
• About your relationships with your family and friends? 
 
Thank you. Now that I have learned a little about you as a person, I will ask you some 
questions about your experiences with FTD.  
 
FTD Journey 
Please tell me about the onset of your FTD.  
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• When and how did your symptoms begin?  
Who first noticed your symptoms? Was it you or someone else? [If someone else, was it a 
family member, doctor, friend, etc.]. 
• What symptoms did you notice? What did other people notice or tell you?  
• What thoughts went through your head when [you or others] started noticing 
symptoms? 
• How would you describe how you were feeling at that time? 
 
What brought you to the [FTD clinic OR research study OR support group]? 
 
Tell me about how things have changed for you since you started to have symptoms.  
• What are some of the biggest changes in terms of [cognitive ability, physical 
ability, relationships with people, outlook on life, daily activities]?  
• Besides [symptoms discussed above], what other symptoms do you have? 
• How have the symptoms affected your life? 
o Physical symptoms? Behavioral symptoms? Cognitive symptoms? 
Emotional symptoms? Changed personality? 
o Tell me about a time when [mentioned symptom] has affected your life. 
o How have the symptoms affected your career? The activities you enjoy 
doing? Who you spend time with? 
• How have the symptoms changed from when they started until now? 
 
Tell me about the time between when your symptoms became noticeable and when you 
were able to get a diagnosis. 
o What was it like to not have a diagnosis?  
o What changed after getting a diagnosis in terms of [your thoughts about 
your symptoms, relationships with people, outlook on life, daily 
activities]? 
 
What have you been told about your symptoms from [name of FTD provider]? 
• What are your reactions to that information?  
• How does it fit with how you thought or felt about your symptoms?  
 
Personhood, Appearance to Self and to Others, Identity 
You’ve told me about how [changes above] have changed for you. Besides these 
changes, how have your symptoms or diagnosis changed the way that you think 
about yourself? 
• The way you feel about yourself? 
 
Tell me about a time when you told someone about your FTD diagnosis. What was it 
like? How did they react? How did you feel?  
 
What changes, if any, have you noticed with your relationships with people close to 
you (care partner, family, friends, etc.)?  
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• What changes, if any, have you noticed in the way people treat you? 
o In the way people talk to you? 
What changes, if any, have you noticed in the way you treat other people? 
Many people with FTD have experiences or interactions with others that stand out 
to them because they were especially positive or especially negative.  
• Tell me about a time when someone made you feel bad about yourself. 
o What do you worry about when you interact with other people? 
o Tell me about a time when someone was embarrassed to be with you. How 
did you feel? 
• Tell me about a time when someone made you feel good about yourself. 
o What do people do that makes you feel valued? Accepted? Understood? 
 
Tell me about an important decision that you had to make recently. How satisfied 
are you with how much you got to decide for yourself? How do you feel about 
whether other people listen to what you had to say? 
• Tell me about a medical decision that had to be made. What was your role in 
making the decision? In participating in the appointment?  
• Tell me about a time when you had to decide about an activity. What was your 
role in making the decision? [employment, hobbies, driving] 
• Who helps you with decision making? How do they help? How do they include 
you? Please give me an example of a time someone helped you make a decision. 
• To what extent do you feel like other people understand you? 
 
How has FTD changed your sense of independence?  
• How do changes in your employment impact your sense of independence? 
o How have financial changes contributed? 
• How do changes in your driving relate to your sense of independence? 
 
What has it meant to you to learn about the genetic/inherited nature of FTD?  
• What, if anything, has it changed for you? For your family? 
 
What do you think [care partner, friends, family] would say about how your symptoms 
have affected you? 
• How would your [care partner, friends, family] say you have changed as a person 
since your symptoms started or since you got your diagnosis?  
• What do you think [care partner, friends, family] would say are your biggest 
challenges? 
• How do you think your [care partner, friends, family] would say your symptoms 
have positively impacted you?  
 
Coping and Management: Facing Challenges, Finding Successes 
What is a bad day for you like? What are the biggest challenges about living with 
your symptoms?  
• What is hardest for you, and why? What do you wish you could do but cannot?  
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• What feelings does this bring up for you? 
 
What strategies do you use to manage [any of the challenges mentioned above]?  
• What are things that you do that help make [above challenges] less challenging? 
 
What is a good day for you like? What are the most important things that you have 
learned from living with your symptoms? 
 
Who helps you with your FTD diagnosis? With emotional support? With physical 
things? With appointments?  
 
How do you get support?  
• Who do you go to when things get tough? Who do you talk to about your 
challenges? How does this [person or provider or organization] help you?  
• What is good about getting support this way? What is bad about it?  
 
How do you feel about the amount of support you are getting?  
• Tell me about a time when you wish that you had more support. 
 
We talked earlier about your initial thoughts and feelings about the genetic testing 
results. We’ve also talked about how you are thinking and feeling about them now. 
Tell me about how you have gotten from your initial reactions to where you are 
now. What has helped with that? What has made it difficult? 
 
How have you dealt with stressful situations in the past? Is that different from how you 
deal with stress now? If so, how? 
 
Future Orientation 
What do you think life will be like for you in the next year? In the next five years? 
How might it be different from your life now? 
 
What worries do you have about the future? What challenges do you think you will 
face? 
 




Some people with FTD experience depression. Tell me about your experiences with 
that. 
 




What do you think is most important for other people to understand about living 
with FTD?  
What is the most important thing for a [a health care provider, care partner, family 
member, friend, colleague] to understand? 
• What would you say to another person who was just diagnosed with FTD? What 
advice would you give them? 
 
I’d like to ask you to be part of my research team for these next few questions. 
Imagine you are now the person in charge of an interview, and the person you are 
interviewing was recently diagnosed with FTD.  
• What questions would you ask them? What would you want to know about 
their experience? What do you think would be important to know about 
them? 
 
Is there anything that you think I should have asked you but didn’t?  
• Is there anything that we didn’t talk about that you feel is important and you 
would like to share? 
 
How do you feel about being in this study? 
 
We are now at the end of our interview. The rest of the research team and I know that 
sharing your experience of living with FTD can be difficult and emotional. We want you 
to know how much we value your responses and hearing your story. Thank you for your 
time and for your answers. Do you have any questions, comments or final thoughts? 
 
Thank you for completing the interview. I will send you the $20 gift card soon.  
 
Would you like me to send you a summary of the results when I finish the project?  
[if yes] Great. I will need to keep your contact information to be able to send you 
the results. Your contact information will not be linked to any other study 
information. Is this okay with you? 
 
 [if no] Okay. I will go ahead and remove your contact information from the study 
database after I mail your gift card. 
 






Interview Summary Sheet 
Interview Summary Sheet 
Participant ID Number: _________________  
Participant type:  Symptomatic     At-Risk 
Date of interview: _____________________  
Interview start time: ___________________  Interview end time: ___________________  
Interview type:  Telephone  In-Person 
Interview location: _____________________  
 
Context of interview (setting, mood, unique situations):  
 
 
Adverse events?  
 
 

























Suggestions for subsequent interviewees: 
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Appendix IV: Recruitment Materials 
Recruitment Prompts 
Email or Mail Prompt 
Hello (name of potential participant),  
 
This is [name of recruiter], a research coordinator in Dr. Grossman’s office at the Penn 
FTD Center. I am contacting you because we have a Masters student, Laynie Dratch, who 
would like to interview you for her thesis research project. She is studying how people 
like you have experienced (living with or living at risk for) FTD.  
 
Laynie would like to contact you to tell you more about her project and how you can 
participate. If you want Laynie to contact you, I need your permission to give her your 
name, email address, phone number, and mailing address. After talking with Laynie, you 
can decide whether or not you want to participate in her study. You would receive a $20 
gift card after participating in the research project. Not every interested person will be 
able to join the study, but you might be a good fit. 
 
If it is okay for Laynie to contact you, she would like me to send you a packet of three 
short forms for the study. Would you prefer this to be via email, fax, or mail? 
 
Please let me know if it is okay to give Laynie your name and contact information. If it is 
okay, please tell me how you want me to send you the study packet.  
 
Thank you for your consideration!  
Best, [name of recruiter] 
 
B. Email or Mail Prompt For When Permission is Received 
Hi (name of potential participant),  
 
Thank you for responding and I am happy to hear that you are interested in joining 
Laynie’s study! I will send you the study packet by [method requested] soon.  
 
In this packet, there are three short forms: 
1. A description of the study and consent information. Please look over this form if you 
have time. Laynie will review this with you in detail over the phone. You keep this form. 
 
2. A short demographics questionnaire. Please answer these questions if you have time. 
Laynie will ask you for the answers on the phone. You keep this form. 
 
3. A HIPAA authorization form. It is important that you send this signed form to Laynie 
as soon as possible. Laynie will not contact you until she has received this form. Laynie’s 
contact information is on this form. This is the only form that you need to sign and return 
to Laynie. 
 
Please let me know if you have any questions or if you do not receive the packet. 
Best, [name of recruiter] 
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C. Telephone Format 
Hi! This is [name of recruiter], a research coordinator in Dr. Grossman’s office at the 
Penn FTD Center. I am calling for (name of potential participant), is this the correct 
person? Hi, (name of potential participant).  
 
I’m calling to talk to you about an FTD research study that you might be interested in. 
 
We have a Masters student, Laynie Dratch, who is interested in interviewing you for her 
thesis project. She is doing a project about how people like you have experienced (living 
with or living at risk for) FTD.  
 
Laynie would like to contact you to tell you more about her project and how you can 
participate. If you want Laynie to contact you, I need your permission to give her your 
name, email address, phone number, and mailing address. After talking with Laynie, you 
can decide whether or not you want to participate in her study. You would receive a $20 
gift card after participating in the research project. Not every interested person will be 
able to join the study, but you might be a good fit. 
 
Do you want Laynie to contact you for her research project?  
 
If they say no: No problem. Thank you for consideration and have a wonderful day!   
 
If they say yes: Great! Is it okay for me to give Laynie your contact 
information? (Participant provides verbal confirmation…) Thank you. I will note your 
permission in your records. 
 
Laynie would like me to send you a packet of forms on her behalf. Do you want me to 
send it to you through email, fax, or postal mail? 
 
Okay, great. I will send you the packet by [method requested] shortly. In this packet, 
there are three forms. The first form is a written version of the study details and consent 
information. Please look over this form if you have time. Laynie will review this with 
you in detail over the phone. The second form is a short demographics questionnaire. 
Please answer these questions if you have time. Laynie will ask you for the answers on 
the phone. The third form is a HIPAA authorization form. It is important that you send 
this signed form to Laynie as soon as possible. Laynie will not contact you until she has 
received this form from you. Laynie’s contact information is written on this form. The 
only form that you need to sign and return to Laynie is the HIPAA authorization form. 
 
Do you have any questions? [Answer questions] 
 
Great, Laynie will contact you as soon as she receives the signed HIPAA authorization 
form. Feel free to reach out to myself or Laynie with any questions. Thanks and have a 




D. In-Person Format 
I wanted to mention an FTD research study that you might be interested in. 
 
We have a Masters student, Laynie Dratch, who is interested in interviewing you for her 
thesis project. She is doing a project about how people like you have experienced (living 
with or living at risk for) FTD.  
 
Laynie would like to contact you to tell you more about her project and how you can 
participate. If you want Laynie to contact you, I need your permission to give her your 
name, email address, phone number, and current mailing address. After talking with 
Laynie, you can decide whether or not you want to participate in her study. You would 
receive a $20 gift card after participating in the research project if you decide to take 
part. Not every interested individual will be able to participate in the study, but you might 
be a good fit! 
 
Are you interested in Laynie contacting you for her research project?  
 
If they say no: No problem.   
 
If they say yes: Great! Is it okay for me to give Laynie your contact 
information? (Participant provides verbal confirmation…) Thank you. I will note your 
permission in your records. 
 
Laynie would like me to give you a packet of forms on her behalf. Here is that packet of 
materials [hand participant packet]. In this packet, there are three forms. The first form is 
a written version of the study details and consent information. Please look over this form 
if you have time. Laynie will review this with you in detail over the phone. The second 
form is a short demographics questionnaire. Please answer these questions if you have 
time. Laynie will ask you for the answers on the phone. The third form is a HIPAA 
authorization form. It is important that you send this signed form to Laynie as soon as 
possible. Laynie will not contact you until she has received this form from you. Laynie’s 
contact information is written on this form. The only form that you need to sign and 
return to Laynie is the HIPAA authorization form. 
 
Do you have any questions? [Answer questions] 
 
Great, Laynie will contact you as soon as she receives the signed HIPAA authorization 




*Note: The recruitment prompts included in this document are those from the University 
of Pennsylvania. Parallel versions of these prompts existed for other recruitment sites. 
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Recruitment Letter 
VOICE Of bvFTD [Voices Of Individuals: Challenges and Experiences of bvFTD] 
Dear (name of potential participant),  
 
You may be able to join a research study about living with or at risk for behavioral variant 
frontotemporal dementia (bvFTD). The study is run by the Johns Hopkins Bloomberg School of 
Public Health, the National Institutes of Health and the University of Pennsylvania. This is an 
interview study. The goal of the study is to learn how bvFTD impacts your day to day life, how 
you think about yourself, and what challenges you face. You might be able to join the study 
because you either have been diagnosed with bvFTD or were found to have a genetic variant 
associated with bvFTD. The study team at [name of site] thought you might be a good fit for the 
study.  
 
The study team hopes this study will help to learn more about the needs of persons at risk or in 
the early stages of bvFTD. The study team hopes what they learn can lead to better future FTD 
care. 
 
If you want to participate in the study, you will have at least two phone calls from the study. 
During the first phone call, which will take about 15 to 20 minutes, you and the researcher will 
review the study in detail together as part of the consent process. The researcher will talk about 
what you are asked to do as part of the study, and potential risks and benefits of joining the study. 
The researcher will ask you some basic questions about yourself and your understanding of the 
study as part of the consent process, and to make sure that you are eligible for the study. The 
study cannot include every interested person, so the study team wants to make sure that each 
person included is a good candidate for the project.  
 
If you are a good match for the project based on that conversation, then you will schedule another 
phone call. During that next call, the researcher will ask you a few more questions about your 
thinking, and you will also complete the interview. The interview questions will be about your 
experiences living with or at risk for bvFTD. Laynie Dratch, a genetic counseling graduate 
student at Johns Hopkins, will interview you. The interview will last about 30 to 60 minutes.  
 
The study team will send you a $20 gift card to thank you for your time if you participate in this 
interview study. It is your decision whether or not you want to join the study. You can discuss the 
study with your family or people that support you if you want to. This might help you decide if 
you want to join the study. You can share the consent form with them if you want. 
 
If you are interested in participating or want more information, please contact Laynie 
Dratch. If you do not want to join the study, please contact Laynie Dratch to let her know. Thank 
you for your time and consideration. The study team looks forward to hearing from you.  
 
Sincerely,  
[Name of provider or site] 
Laynie Dratch, B.A.  
Student Investigator 
JHU/NHGRI Genetic 
Counseling Training Program  





Jill Owczarzak, PhD  
Principal Investigator 
Johns Hopkins Bloomberg 
School of Public Health 
Baltimore, MD  
Phone: 410-502-0026 
Email: jillowczarzak@jhu.edu   
 
Lori Erby, PhD, ScM, CGC  
Associate Investigator   
Medical Genomics/Metabolic 
Genetics Branch 






VOICE Of bvFTD [Voices Of Individuals: Challenges and Experiences Of bvFTD] 
 
The VOICE Of bvFTD study is currently seeking volunteers to learn more about 
experiences of living with or at risk for developing behavioral variant frontotemporal 
dementia (bvFTD) as part of a multicenter research project on bvFTD. The study will 
involve interviews to help us learn as much as possible about living with bvFTD. We 
hope that this will guide future research, resource development, and clinical practice. 
  
The study is called VOICE Of bvFTD. You must be 18 years of age or older and speak 
English to participate. You may be able to take part in this study if you are:   
 
• A person who has bvFTD 
OR 
• A person who is at risk of developing bvFTD in the future because of an 
identified disease-causing change in a gene that is known to cause bvFTD, such as 
the C9orf72 gene 
 
 
The goal of the VOICE Of bvFTD project is to better understand how people perceive 
life with or at risk for bvFTD. We want to know how the disease affects your day to day 
experiences, how you think about yourself, and how you overcome challenges.  
 
What’s involved for a research participant? 
 
If you participate, you will have at least two phone calls from us. During the initial phone 
call, which will take about 15 to 20 minutes, we will ask you some basic questions about 
yourself and we will review the study together as part of the consent process. During 
another call we will ask some questions to assess your thinking and complete the 
interview, which will last about 30 to 60 minutes. There are no physical or medical 
procedures included in this study. The consent process, screening, interview scheduling, 
and the interview itself will take place over two to three phone calls, which may occur 
over several weeks. You will be given a $20 gift card for your time if you participate in 




If you are interested in this study or have any questions, please contact the VOICE Of 







VOICE Of bvFTD [Voices Of Individuals: Challenges and Experiences Of bvFTD] 
 
We are currently seeking volunteers to learn more about experiences of living with or at 
risk for developing behavioral variant frontotemporal dementia (bvFTD) as part of a 
multicenter research project on bvFTD. The study will involve interviews to help us learn 
as much as possible about living with bvFTD. We hope that this will guide future 
research, resource development, and clinical practice. 
  
The study is called VOICE Of bvFTD. You may be able to take part in the VOICE Of 
bvFTD study if you are:   
 
• A person who has bvFTD 
OR 
• A person who is at risk of developing bvFTD in the future because of an 
identified disease-causing change in a gene that is known to cause bvFTD 
 
The goal of the VOICE Of bvFTD project is to better understand how people perceive 
life with or at risk for bvFTD. We want to know how the disease affects your day to day 
experiences, how you think about yourself, and how you overcome challenges.  
 
 
What’s involved for a research participant? 
 
If you participate, you will have at least two phone calls from us. During the initial phone 
call, which will take about 15 to 20 minutes, we will ask you some basic questions about 
yourself and we will review the study together as part of the consent process. During 
another call we will complete the interview, which will last about 30 to 60 minutes. There 
are no physical or medical procedures included in this study. The consent process, 
screening, interview scheduling, and the interview itself will take place over multiple 
phone calls, which may occur over several weeks. You will be given a $20 gift card for 




If you are interested in this study or have any questions, please contact the VOICE Of 
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